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ABSTRACT 
 
SARAH C. JACKSON: Genetic analysis of Vprbp in mice  
(Under the direction of Dr. Yue Xiong) 
 
 
Ubiquitin-mediated protein degradation is a critical mechanism for regulating many 
cellular functions.  Substrate proteins are specified through the activity of an E3 ubiquitin 
ligase.  Cullin proteins serve as scaffolds to assemble hundreds of distinct multi-subunit 
E3 ubiquitin ligase complexes.   My research focused on CUL4-based complexes, which 
use linker protein DDB1 to bind one of approximately 100 putative substrate recruiting 
proteins.  Specifically, I investigated HIV1 viral protein R binding protein (VprBP), a 
WD40 repeat-containing protein which binds to CUL4-DDB1 and is predicted to function 
as a substrate recognition subunit.  Functional studies of VprBP remain limited; there are 
currently no known substrates for CUL4-DDB1-VprBP and Vprbp knockout mice are 
early embryonic lethal.  In my work, I first tested a hypothesis that VprBP functions in 
epigenetic modification of histones and intriguingly observed a possible role in histone 
H4 ubiquitylation.  My subsequent work focused on understanding the function and 
mechanism of Vprbp by analyzing conditional mouse embryonic fibroblasts (MEFs) and 
mice.  I discovered that VprBP is required for MEF proliferation and paradoxically that 
high levels of VprBP protein are associated with quiescent cells.  Finally, by crossing 
conditional Vprbp mice with transgenic Ubiquitin C promoter driven Cre-ERT2+ mice, I 
was able to temporally control Vprbp disruption in an unbiased manner to explore 
phenotypes beyond embryonic lethality  This work uncovered a role for Vprbp in the 
proliferation and survival of lymphocytes in mice.  
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Ubiquitin-mediated protein degradation  
Appropriate degradation of specific proteins is crucial for a number of cellular 
functions including cell cycle progression, induction of apoptosis, and DNA damage 
response.  Most proteins regulated by degradation are targeted by the ubiquitin-
proteasome system.  Ubiquitin is a small protein which can be covalently linked to a 
substrate protein or to another ubiquitin through the enzymatic cascade known as 
ubiquitylation (Pickart, 2001).  Ubiquitylation proceeds through an E1 (ubiquitin-
activating enzyme), an E2 (ubiquitin-conjugating enzyme) and an E3 ubiquitin ligase 
(substrate targeting protein).    The C-terminal glycine of ubiquitin (Ub1) is bound to a 
lysine residue on the substrate.  Subsequently, an additional ubiquitin (Ub2) can be 
ligated to a lysine on Ub1 to form a polyubiqutin chain.  Substrates with lysine 48 linked 
polyubiquitin chains are rapidly detected and degraded by the 26S proteasome.  In 
addition, some substrates are mono-ubiquitylated or polyubiquitylated through chains 
linked by other lysine residues in ubiqutin (K6R, K11R, K27R, K29R, K33R, or K63R).  In 
these cases, ubiquitylation may not direct proteolysis, but rather appears to function like 
other post-translational modifications, regulating protein conformation, localization or 
binding partners.  
Eukaryotes typically have one E1 ubiquitin activating enzyme, and a limited 
number of E2 ubiquitin conjugating enzymes (13 in S. cerevisiae, 22 in C. elegans, 30 in 
humans) (Kipreos, 2005). In contrast, a large number of E3 ubiquitin ligases are found, 
and substrate binding by the ubiquitin ligase is critical for conferring specificity to 
proteolysis.  There are two major families of E3 ligases distinguished by their active 
domains: the HECT family ('homologous to the E6-AP carboxy terminus') and the RING 
family (containing a cross-braced structure characterized by cysteine and histidine 
residues that bind to zinc atoms and first recognized in the human 'really interesting new 
gene product') (Freemont, 2000; Huibregtse et al., 1995; Lovering et al., 1993). The 
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HECT domain mediates interaction with the cognate E2 and, through an evolutionarily 
conserved cysteine residue, forms a thioester linkage with ubiquitin. Human cells contain 
as many as 28 HECT proteins and most, if not all, are believed to function as E3 ligases. 
Unlike the HECT domain, the RING domain promotes a direct transfer of ubiquitin from 
the E2 to the substrate without forming an intermediate with ubiquitin. Human cells 
express more than 450 RING proteins, and E3 ligase activity has been experimentally 
demonstrated for many of them.  A ubiquitin ligase can be a single protein with an 
intrinsic RING finger domain or a multi-subunit complex which contains a RING finger 
protein.   
 
Cullin Family Ubiquitin Ligases 
Although not containing a RING domain themselves, members of the 
evolutionarily conserved cullins constitute a large family of cullin-RING E3 ligases 
(CRLs).  The highly conserved C-terminal domain of the cullin binds with a RING finger 
protein, ROC1 (RING of cullins; also known as Rbx1 or Hrt1) or ROC2, and facilitates 
transfer of ubiquitin from E2.  There are three cullins in yeast, six in Caenorhabditis 
elegans and Drosophila melanogaster (CUL1-6), up to nine in Arabidopsis thaliana, and 
six canonical cullins in humans (CUL1, 2, 3, 4A, 4B and 5).  In addition, three other 
proteins, CUL7 and CUL9 (also known as PARC) in mammals and APC2 (anaphase 
promoting complex subunit 2) in all eukaryotes, contain significant sequence homology 
to cullins over a ~180 residue region and bind ROC or a homologous small RING finger 
protein, APC11.  Cullins do not bind substrates directly, but rather rely on substrate 
recruiting receptors that are joined to the cullin complex by a linker protein (Figure 1.1). 
Cullins serve as bona fide scaffold proteins, assembling substrate targeting and RING 
finger proteins into a single complex.  Remarkably, each cullin can associate with a  
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Figure 1.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.1. Cullin-RING ubiquitin ligases (CRLs).   
 
Each cullin uses modular assembly to recruit different substrates to a common catalytic 
core by varying its substrate receptor. Cullin family members (green) from different 
organisms share similar mechanisms for assembling a multi-subunit complex to 
ubiquitylate specific substrate protein (light blue). An N-terminal domain interacts either 
directly with a protein motif (orange) present in substrate receptors (black) or via a linker 
(blue). Separately, a C-terminal domain binds with a small RING protein (ROC1 or 
ROC2, yellow) which recruits and allosterically activates an E2 enzyme (red) that 
transfers ubiquitin to the substrate. Cullins are activated by the covalent conjugation with 
the ubiquitin-like modifier, NEDD8 (Nd8; purple).  
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different family of substrate receptors, leading to the assembly of as many as 400 
distinct CRLs.  A recent estimate suggests that 20% of all proteins subject to 
proteasomal degradation are targeted by CRLs (Soucy et al., 2009). 
 
The founding cullin gene, Cul1(also called Cdc53 in budding yeast), was first 
identified in Saccharomyces cerevisiae where its mutation blocked the G1-to-S transition 
(Mathias et al., 1996) and led to an accumulation of G1 cyclin (Willems et al., 1996), and 
was separately identified in C. elegans where loss of Cul1 function caused hyperplasia 
of multiple tissues (Kipreos et al., 1996). These diverse or even seemingly irreconcilable 
phenotypes were subsequently explained by the discovery that CUL1 can assemble into 
distinct E3 complexes and thereby ubiquitylate multiple substrates. CUL1 binds a small 
protein, SKP1 (S-phase kinase-associated protein 1), which in turn binds a conserved 
protein motif, the F-box, which is present in many different proteins (Bai et al., 1996).  
Through additional protein–protein interaction modules, individual F-box proteins can 
then recruit different substrates to the CUL1–ROC1–E2 catalytic core (Zheng et al., 
2002b). In this modular SKP1–CUL1–F-box (SCF) assembly, CUL1 indeed acts as a 
scaffold, SKP1 as a linker and F-box proteins as substrate receptors (Figure 1.1).  By 
only varying the substrate targeting receptor, many different substrates can be 
ubiquitylated by a shared catalytic core.           
Each cullin interacts with a distinct family of substrate targeting receptors through 
the divergent N-terminal domain of the cullin.  To bring specific substrates to CUL2- and 
CUL5-based ligases, a heterodimeric linker complex containing Elongins B and C binds 
to an analogous N-terminal domain in CUL2 and CUL5 and to two similar protein motifs, 
the VHL-box and SOCS box.  VHL and SOCS proteins, via their additional protein–
protein interaction modules, target various substrates differentially to the CUL2–ROC1–
E2 or CUL5–ROC2–E2 catalytic cores, respectively (Kamura et al., 2004).  Omitting a 
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linker, CUL3 utilizes its N-terminal domain to bind to a conserved 100-residue protein 
motif known as a BTB  domain, which then target substrates to the CUL3–ROC1–E2 
catalytic core (Furukawa et al., 2003; Geyer et al., 2003; Pintard et al., 2003b; Xu et al., 
2003) (Figure 1.1).  CUL4-based E3 ubiquitin ligases use DDB1 as a linker protein and a 
subset of WD40 proteins, known as DWD proteins, serve as the substrate receptor 
(discussed in detail below).  Cullins control the ubiquitylation of a wide variety of 
substrates, and form the largest known family of ubiquitin ligase complexes -- mammals 
express approximately 70 F-box proteins, 30 BC-box proteins, 200 BTB proteins, and 
100 DWD proteins.  My thesis research focused on a specific DWD protein, VprBP, 
which functions as part of a CUL4-based complex.  
 
Regulation of CRL Complexes 
 Assembly and activation of cullin complexes must be carefully regulated.  CUL1, 
and CUL3 complexes have been noted to form dimers in vivo, and, in the case of CUL1, 
dimerization was required for elongation of ubiquitin chains (Chew et al., 2007; Tang et 
al., 2007).  All cullins require post-translational modification by NEDD8, a ubiquitin-like 
proteins, to form an active ubiquitin ligase complex.  Cullin-bound NEDD8 can directly 
bind E2, promoting E2 recruitment and possibly facilitating the processivity of 
polyubiquitylation (Sakata et al., 2007; Kawakami et al., 2001; Saha and Deshaies, 
2008). Like modification by ubiquitin, modification with NEDD8 requires an enzymatic 
cascade consisting of an E1 (heterodimeric NAE1/UBA3), E2 (UBC12) and E3 
(consisting of the scaffold protein DCN1 and ROC1) (Liakopoulos et al., 1998; Gong and 
Yeh, 1999; Kurz et al., 2008; Kurz et al., 2005; Morimoto et al., 2003).  A recently 
developed cullin inhibitor, MLN4924, functions by blocking the activity of the NEDD8 E1, 
further underscoring the requirement for neddylation for cullin function (Soucy et al., 
2009).  
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There are three primary ways to negatively regulate cullin activity: auto-
ubiquitylation of substrate targeting receptors, binding to a negative regulator (CAND1), 
and removal of NEDD8 modification.  In the absence of substrate binding, cullins have 
been frequently shown to ubiquitylate their own substrate targeting receptors, thereby 
inactivating the complex (Galan and Peter, 1999; Wirbelauer et al., 2000; Li et al., 2004; 
Chen et al., 2001; Zhou and Howley, 1998).  CAND1 (cullin-associated and neddylation 
dissociated) binds to N-terminal and C-terminal regions of cullins, masking sites in the 
cullin N-terminus required for the binding with linker proteins (Liu et al., 2002; Zheng et 
al., 2002a; Goldenberg et al., 2004). Finally, removing NEDD8 from a cullin (known as 
deneddylation) inactivates the catalytic core.  Deneddylation requires the COP9 
signalosome (CSN), an eight subunit complex that shares homology with the 
proteasome lid (Cope and Deshaies, 2003).    
While biochemical studies of CSN and CAND1 have shown evident negative 
regulation of CRL complexes, genetic analysis of CSN genes and CAND1 has revealed 
more complicated interactions.  In Arabidopsis, loss of genes encoding CSN subunits led 
to an accumulation of neddylated cullins but paradoxically did not lead to a depletion of 
SCF substrates such as AUX/IAA (Schwechheimer et al., 2001).  Likewise, loss of CSN 
reduced activity of CRL3 complexes in C. elegans despite elevated levels of neddylated 
CRL3 (Pintard et al., 2003a).  These results suggested a model that cycles of 
neddylation and deneddylation are required for cullin ubiquitin ligase activity and 
potentially functions to prevent autoubiquitylation of substrate recruiting receptors (Cope 
and Deshaies, 2006; He et al., 2005; Wu et al., 2005).  In the case of CAND1, while 
biochemical studies indicate CAND1 is a general CRL inhibitor, genetic studies suggest 
a more nuanced role.  Studies in Arabidopsis, S. pombe, and C. elegans show that 
CAND1 is required for the function of at least a subset of CRL complexes, but does not 
appear to globally regulate levels of neddylated cullins (Zhang et al., 2008; Schmidt et 
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al., 2009; Bosu et al., 2010).  A current model suggests that CAND1 may function to 
facilitate the formation of rare CRL complexes, even in the presence of more abundant 
substrate recruiting receptors (Schmidt et al., 2009), but additional studies will be 
required to clarify the precise in vivo function of CAND1.  Nevertheless, it’s clear cells 
rely on multiple levels of regulation to precisely control the assembly of the appropriate 
cullin family ubiquitin ligase complexes.    
 
CRL4 complexes  
Following the discoveries that CUL1, CUL2 and CUL3 each interacts with 
multiple substrate receptors and that CUL4 performs pleiotropic functions, it was 
anticipated that CUL4 very likely would also interact with a protein motif present in 
multiple proteins. Taking different approaches -- proteomic, bioinformatic and structural 
analyses -- four independent studies collectively identified and experimentally 
demonstrated 52 different DDB1 binding WD40 proteins, referred to variously as DWD 
(DDB1-binding WD40), DCAF (DDB1–CUL4 associated factors) or CDW (CUL4–DDB1–
associated WDR) proteins (He et al., 2006; Higa et al., 2006b; Angers et al., 2006; Jin et 
al., 2006; and reviewed in Lee and Zhou, 2007). It was also clear that only a subset of, 
but not all WD40 proteins, interact with DDB1 and CUL4. DDB1-binding proteins contain 
a common motif, variably defined as the “double DxR box” with two DxR motifs located 
at the end of two consecutive WD40 repeats (Angers et al., 2006), the “DWD box”, a 16-
residue stretch that correspond to the second half of a WD40 repeat and an Arg residue 
at position 16 following the WD dipeptide (He et al., 2006), the “DXXXR/KXWDXR/K” 
motif as the subdomain of WD40 repeats (Higa et al., 2006b), or simply as the “WDXR” 
motif to emphasize the Arg residue following the WD dipeptide (Jin et al., 2006).  Some 
DWD proteins contain one, most contain two and a few contain three such motifs.   
 9 
 
Mutational analysis and conservation of the WDXR motif in all DWD proteins 
initially suggested that this motif directly mediated binding with DDB1.  However, a co-
crystal structure of human DDB1 and zebrafish DDB2 unexpectedly revealed that the 
corresponding Arg residue in zebrafish DDB2 (Arg309) did not contact DDB1 (Scrima et 
al., 2008), though mutation of the WDXR motif in DDB2 disrupted binding to DDB1 
(Rapic-Otrin et al., 2003).   In addition, WDTC1 (Li et al., 2010a) and WDR21 (Fukumoto 
et al., 2008) were also shown to bind to DDB1 independently of their WDXR motifs.  An 
alpha-helical region in these proteins termed the H-box, which has structural similarity 
with DDB1-binding viral protein SV5 (Li et al., 2010a), but is clearly distinct from the 
WDXR motif, was required for binding.  The H-box was identified by sequence homology 
in seven DWD proteins, though the vast majority of DWD proteins lacked an H-box, at 
least as determined by primary sequence homology (Li et al., 2010a).  It remains 
possible that divergent primary sequence might converge to a similar alpha-helical 
structure, though this has yet to be demonstrated.  Although a consensus sequence for 
residues that contact DDB1 is not yet precisely defined for most DWD proteins, the 
current definition of the DWD motif is highly predictive of and likely structurally important 
for DDB1 binding proteins.  Future studies will be needed to further understand why the 
DWD motif is so critically important in CRL4 substrate receptors. 
 How many DWD proteins are there?  The human genome encodes about 320 
unique WD40 proteins. Database searches using the DWD box predicted that 78 unique 
DWD proteins could bind to DDB1; 25 of these proteins were experimentally validated in 
the 2006 papers which established DDB1-WD40 protein binding (He et al., 2006; Higa et 
al., 2006b; Angers et al., 2006; Jin et al., 2006; my unpublished analysis of the dataset). 
An additional 27 proteins, which contain the smaller WDXR or WDXK consensus 
sequence, have been experimentally demonstrated to bind DDB1, suggesting DDB1 
binds as many as 105 different WD40 proteins (He et al., 2006; Higa et al., 2006b; 
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Angers et al., 2006; Jin et al., 2006).   Similar searches of the DWD motif predicted 33 
DWD proteins in fission yeast, 36 in C.elegans, 75 in Drosophila, 78 in rice and 85 in 
Arabidopsis (He et al., 2006; Lee et al., 2008).  When 11 predicted Arabidopsis DWD 
proteins were tested for their direct interaction with DDB1 by yeast two-hybrid assay, all 
were found to be positive (Lee et al., 2008), suggesting that most of these predicted 
DWD proteins indeed bind to DDB1.  
 
Genetic analysis of CUL4 and DDB1 
A single CUL4 gene exists in Schizosaccharomyces pombe, C. clegans, 
Drosophila, and Arabidopsis whereas mammalian cells express two closely related 
paralogues, CUL4A and CUL4B.  Two closely related CUL4 genes are also present in 
zebrafish and frog, but not in sea urchin, suggesting that the CUL4 gene duplication is 
unique to vertebrates. Characterization of null mutations or reduced expression of CUL4 
in these organisms has revealed a wide range of cellular and organismal defects, 
including many associated with deregulated chromatin.  
 
S. pombe Cul4 mutations cause multiple chromatin defects 
Cul4 (also known as pcu4) deletion in fission yeast results in extremely elongated 
cells with a severely reduced growth rate and decondensed chromosomes (Osaka et al., 
2000). The defect in chromosome condensation can be attributed in part to a role for 
Cul4 in maintaining the heterochromatin formation through its interaction with Rik1, a 
protein that is distantly related to mammalian DDB1.  Cul4, using Rik1 as linker protein, 
binds with Clr4 histone H3K9 methyltransferase and is required for Clr4 localization to 
heterochromatin (Horn et al., 2005; Jia et al., 2005; Thon et al., 2005).  Further, this 
complex was shown to require ubiquitin ligase activity, as a expression of a Cul4 mutant 
lacking the Nedd8 modification site could not compensate for cul4D (Jia et al., 2005).   
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C.elegans cul-4 mutations cause CDT1 accumulation and DNA re-replication 
Inactivation of cul-4 in C.elegans by RNA interference (RNAi) resulted in a 
developmental arrest at the L2 larval stage and caused massive DNA re-replication 
(Zhong et al., 2003). In cul-4 RNAi animals, there was sustained accumulation of the 
DNA replication-licensing factor, CDT-1 (chromatin licensing and DNA replication factor 
1), after S-phase completion whereas wild-type cells expressed undetectable CDT-1 
(Zhong et al., 2003).  Additionally, nuclear export of the other replication licensing factor, 
Cdc6, was inhibited indirectly due to a failure to ubiquitylate the p21 homolog, CKI-1, 
thus contributing to the dramatic re-replication phenotype (Kim et al., 2007). Removal of 
one genomic copy of cdt-1 suppressed the cul-4 re-replication phenotype (Zhong et al., 
2003). These results demonstrated a function for CUL-4 in maintaining genome stability 
in part by facilitating CDT-1 degradation during the cell cycle and preventing aberrant 
licensing of DNA replication. 
 
Arabidopsis CUL4 mutations impair development 
Arabidopsis CUL4 is expressed abundantly and broadly in almost all tissues 
examined. Arabidopsis expresses two different CUL4 isoforms from a single gene, with 
one (CUL4-L) containing an additional 50 amino acid sequence at the N-terminus absent 
in the other (CUL4-S).  Reduced CUL4 expression in Arabidopsis by transgene-
mediated co-suppression or RNAi results in pleiotropic cop-like (constitutive 
photomorphogenesis) phenotypes and widespread developmental defects in lateral 
roots, abnormal vascular tissue, and stomatal development (Chen et al., 2006; 
Bernhardt et al., 2006), providing genetic evidence supporting the notion that CUL4 can 
assemble multiple distinct CRL4 complexes and regulate many different substrates.  
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Figure 1.2 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Schematic comparison of CUL4 proteins and mouse Cul4A mutants. 
   
(A) Human cells contain two CUL4 genes encoding CUL4A (NP_001008895) and two 
isoforms of CUL4B (NP_001073341 and NP_003579.3) proteins which differ by only 22 
amino acids at the N-terminus.  The extended N-terminus of CUL4B contains a nuclear 
localization signal (NLS).    
 
(B) Wild type mouse Cul4A gene and comparison of three targeted Cul4A mutants.  
Filled and open boxes denote coding and non-coding exons, respectively.  Exons 
encoding the DDB1 and ROC 1 binding regions in CUL4A have been noted.  Three 
mouse models targeting Cul4A have been generated to date, deleting exon 1, exons 4-
8, and exons 17-19, respectively.  Discrepancies in reported phenotypes might be due to 
unintentional disruption of a nearby neighboring gene, Pcid2. 
  
A
B
913CUL4B, isoform 1
CUL4A
DDB1
ROC Nd
8
CUL4B, isoform 2 895
759
N
d
8
N
d
8
Pcid2 Cul4A
ATG STOP
DDB1 binding
1 2 3 4 56 9 10 12-15 16 1718  19        20
ATG
7  8 11
ROC1 binding
D1 D4-8 D17-19
N
L
S
N
L
S
 13 
 
Mammalian CUL4A and CUL4B are not entirely redundant 
In mammals, genetic analysis of CUL4 function is complicated by the existence 
of two closely related genes, CUL4A and CUL4B, which encode proteins sharing 80% 
identity (Figure 1.2A). CUL4B contains additional N-terminal residues and a nuclear 
localization signal (Zou et al., 2009).  A Cul4A mutant mouse created by deleting exon 1 
(Cul4AD1/D1, Figure 1.2B) was reported to cause early embryonic lethality (Li et al., 2002) 
and widespread defects in hematopoeisis when conditionally deleted (Li et al., 2007).  
This phenotype led to the early impression that the two CUL4 genes in mammals are 
functionally distinct.  Recently, a different Cul4A mutant mouse strain, targeting exons 
17-19 (Cul4AD17-19/D17-19) which encode the ROC binding region and Nedd8 modification 
site, unexpectedly showed no apparent phenotype (Liu et al., 2009).  This significant 
discrepancy was explained by the inadvertent disruption in the Cul4AD1/D1 mutant strain 
of a very close neighboring gene, Pcid2, which encodes an uncharacterized protein with 
homology to essential proteasome subunits (Liu et al., 2009).  Supporting this 
explanation, deletion of exons 4-8 (Cul4AD4-8/D4-8), which encode for a portion of the 
DDB1 binding domain, resulted in only a mild decrease in the proliferation in mouse 
embryonic fibroblasts (MEFs) and viable mice with male infertility (Kopanja et al., 2011; 
Kopanja et al., 2009).   
 Despite their high degree of sequence homology, wide expression and apparent  
 compensation for Cul4A loss by Cul4B in the mouse, the two Cul4 genes are not 
entirely functionally redundant. Deletion of exons 17-19 of Cul4 resulted in an increase in 
stability of several CRL4 substrates (discussed in detail below), including DNA repair 
factors DDB2 and xeroderma pigmentosum complementation group c (XPC) as well as 
CDK inhibitor p21.  Furthermore, DDB2-dependent global genomic repair activity was 
enhanced and Cul4AD17-19/D17-19  mice had increased resistance to UV-induced skin 
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cancer (Liu et al., 2009).  These findings, which are consistent with the enhanced 
resistance to UV-induced carcinogenesis in DDB2 transgenic mice (Alekseev et al., 
2005), point to a role for CUL4A in restricting the activity of DNA damage responsive 
proteins by promoting DDB2 degradation, a function that is apparently not fully 
compensated by CUL4B.   
Using a screen to inactivate genes on the X-chromosome in mice by gene-trap, 
Cul4b was recently shown to be required for mouse embryonic development; Cul4b 
disruption resulted in incomplete embryo turning, as well as defective neural and cardiac 
development (Cox et al., 2010).  These genetic results demonstrate that while CUL4B 
can compensate for loss of Cul4a, CUL4A is unable to compensate for loss of Cul4b.  In 
humans, several familial mutations in CUL4B have been identified in association with X-
linked mental retardation (XLMR); the majority of mutations result in frame-shift and 
truncation, indicating that loss-of-function of CUL4B contributes to XLMR (Tarpey et al., 
2007; Zou et al., 2007).  It is not entirely clear why loss of Cul4b leads to embryonic 
lethality in mice while in humans CUL4B mutation leads to XLMR.   
Supporting a distinct genetic function of CUL4B gene, the N-terminus of CUL4B, 
but not CUL4A, has been shown to uniquely bind to the dioxin receptor (AhR), 
assembling a CUL4B specific ubiquitin ligase complex that targets estrogen receptor α 
(ER-α) for degradation (Ohtake et al., 2007). DDB1, the linker that is commonly used by 
both CUL4A and CUL4B for interacting with different substrate receptors, was identified, 
along with CUL4B in the AhR-immouncomplex, but its function in promoting CUL4B-
mediated substrate degradation remains unclear as it was not apparently required for 
substrate recruitment.  In addition, the Xiong lab recently discovered that CUL4B, but not 
CUL4A, promotes the ubiquitylation of WDR5, a core component of the trimeric MLL1 
histone H3K4 methyltransferase complex (Nakagawa and Xiong, 2011, in press).  The 
specificity of CUL4B for WDR5 is due primarily to a nuclear localization signal in the N-
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terminus of CUL4B which is required for co-localization with WDR5.  Thus biochemical 
and genetic data support the conclusion that CUL4B has unique functions for which 
CUL4A cannot compensate in vivo. 
 
The Ddb1 gene is required for development and DNA repair 
Like CUL4, DDB1 is essential for development in multiple organisms.  
Knockdown of DDB1 in Drosophila caused lethality early in development (Takata et al., 
2004). Ddb1 is allelic to a previously defined locus termed piccolo (pic) (Hu et al., 2008). 
Semi-lethal piccolo mutants were originally characterized based on shared irregularities 
in bristle, wing, and body segment growth (Clark and Chovnick, 1986). Ddb1 mutants 
growth arrest at the second instar stage, thus failing to develop completely (Hu et al., 
2008). In addition, knockdown of DDB1 in wing imaginal disks caused increased 
sensitivity to methyl-methanesulfonate (MMS)-induced DNA damage (Shimanouchi et 
al., 2006).   
Unlike other model organisms, Arabidopsis contains two DDB1 genes, AtDDB1A 
and AtDDB1B, complicating the assessment of the functional dependency of CUL4 on 
DDB1. AtDDB1B disruption is lethal whereas the only effect of homozygous loss of 
AtDDB1A is decreased UV tolerance for a short period of time immediately following UV 
irradiation (Al Khateeb and Schroeder, 2009; Schroeder et al., 2002). The inability of 
AtDDB1A to complement AtDDB1B is puzzling given that AtDDB1A is 91% identical to 
AtDDB1B over the entire 1088 residues, also binds to AtCUL4 (Bernhardt et al., 2006), 
and is widely and concurrently expressed in many tissues; however AtDDB1B is often 
expressed at higher levels (Al Khateeb and Schroeder, 2007).  
Ddb1 knockout in mouse resulted in lethality prior to embryonic day 12.5, and 
conditional deletion in brain and lens tissue using Nestin-Cre resulted in accumulation of 
CDT1, accumulation of DNA damage, and apoptosis of proliferating neuronal progenitor 
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cells (Cang et al., 2006). Crossing these mice to mice lacking the tumor suppressor 
gene encoding p53 (TP53) partially rescued the apoptotic defect, but surviving cells 
showed irregularly shaped nuclei and high frequency of mitotic division (Cang et al., 
2006).   The Nestin-Cre; Ddb1F/F mice and the Nestin-Cre; Ddb1F/F; TP53-/- mice died at 
day one post-birth (Cang et al., 2006).   
Deletion of ddb1 in fission yeast resulted in cells that are viable, but are 
hypersensitive to various DNA damage agents, delayed in DNA replication progression, 
accumulate DNA damage, and show elongated phenotypes, abnormal nuclei and 
retarded growth (Holmberg et al., 2005; Zolezzi et al., 2002).  Many of these phenotypes 
are similar to those observed in cul4D cells (Osaka et al., 2000), Notably, S. pombe 
contains an additional protein, Rik1 that shares 21% identity with DDB1 and also 
assembles into E3 ligases with Cul4.  However, the use of multiple adaptor proteins in 
CRL4 ligases is not evolutionarily conserved as metazoans do not contain a Rik1 
homolog. 
 
Cullin 4 ubiquitin ligase complexes in DNA replication & repair 
CUL4-DDB1 complexes have frequently been reported in regulating DNA 
damage response.  DDB2 and CSA encode two related WD40 proteins which control 
two different pathways of nucleotide excision repair, global genome repair  and 
transcription-coupled repair, and when mutated they lead to two distinct hereditary 
diseases, xeroderma pigmentosum and Cockayne syndrome, respectively. In a search 
for the molecular basis underlying the function of DDB2 and CSA in DNA repair, it was, 
at the time, surprising to find that they assemble into similar complexes that contain 
DDB1, CUL4A, ROC1 and all 8 subunits of COP9 signlaosome (Groisman et al., 2003). 
This study provided the initial basis for recognizing the importance of CRL4 complexes 
in DNA repair (discussed further below and in Chapter 2).  In addition, multiple lines of 
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genetic and biochemical research established DDB1 as an essential component for 
CDT1 ubiquitylation by the CUL4A–ROC1–E2 catalytic core (Hu et al., 2004; Cang et al., 
2006).  These studies, as well as cul-4 studies by the Kipreos lab and work by the Walter 
lab in Xenopus extracts, firmly established the role of CRL4 in regulating DNA replication 
through targeted ubiquitylation of the DNA licensing factor CDT1 (Jin et al., 2006; Zhong 
et al., 2003).   Subsequent studies broadened the function of CRL4 complexes in DNA 
replication, repair and beyond. 
 
PCNA is required for the ubiquitylation of multiple PIP box proteins by CRL4CDT2   
A unique feature of CRL4CDT2-mediated CDT1 ubiquitylation is the requirement of 
proliferating cell nuclear antigen (PCNA), (Nishitani et al., 2006; Arias and Walter, 2006; 
Hu and Xiong, 2006; Senga et al., 2006) a cofactor of DNA polymerases that functions 
as a sliding clamp encircling DNA (Moldovan et al., 2007).  The function of PCNA in 
CRL4CDT2-mediated ubiquitylation remains unclear, but is not limited to CDT1 alone. 
Recently, additional CRL4CDT2 substrates, CDK inhibitor p21 (Nishitani et al, 2008; Kim 
et al, 2008; Abbas et al, 2008), C. elegans polymerase η (Kim and Michael, 2008), 
Drosophila E2f1 (Shibutani et al., 2008), PR-SET7 (Abbas et al., 2010; Centore et al. 
2010, ; Jorgensen et al., 2011; Oda et al., 2010) and S. pombe JmjC family protein Epe1 
(Braun et al., 2011), have all been reported to be degraded in a PCNA-dependent 
manner. All reported CRL4CDT2 substrates contain a conserved PCNA-interacting motif 
(PIP box) and bind PCNA directly.  Further, this direct binding is required for their 
ubiquitylation. Although the human genome encodes 47 PIP box proteins, and most  
have chromatin-associated functions (Moldovan et al., 2007), only a subset are 
predicted to bind CDT2 (Havens and Walter, 2009).     
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Table 1.1. CRL4 Substrates 
Substrate Function Receptor Organism
a
 Reference 
CDT1 
                    
                      
DNA replication CDT2  Hs, Xl, 
Dm, Ce, 
Sp 
(Arias and Walter, 2005, 2006; Higa et al., 
2006a; Higa et al., 2003; Hu et al., 2004; 
Hu and Xiong, 2006; Jin et al., 2006; 
Nishitani et al., 2006; Sansam et al., 2006; 
Senga et al., 2006; Zhong et al., 2003) 
p21     Cell cycle inhibitor CDT2  Hs, Ce (Nishitani et al., 2008) (Kim et al., 
2008)(Abbas et al., 2008) 
E2F1 Cell cycle/ 
transcription factor 
CDT2 Dm (Shibutani et al., 2008) 
pol η DNA replication 
during damage 
CDT2 Ce (Kim and Michael, 2008) 
Spd1  DNA replication 
inhibitor 
Cdt2  Sp (Bondar et al., 2004; Holmberg et al., 
2005; Liu et al., 2005; Liu et al., 2003) 
Epe1             Histone demethylase                Cdt2   Sp   (Braun et al., 2011) 
PR-SET7/ 
SET8                                    
Histone H4 
methyltransferase                               
CDT2 Hs   (Abbas et al., 2010; Centore et al., ; 
Jorgensen et al., 2011; Oda et al., 2010) 
PCNA DNA replication/ 
repair 
CDT2 Hs (Terai et al., 2010) 
Histones 
H2A, H3, 
H4 
Chromatin formation DDB2  Hs (Kapetanaki et al., 2006; Wang et al., 
2006) 
XPC  DNA damage repair DDB2  Hs (Sugasawa et al., 2005) 
DDB2  DNA damage repair
  
DDB2 Hs (El-Mahdy et al., 2006; Sugasawa et al., 
2005) 
CSB DNA damage repair CSA Hs (Groisman et al., 2006) 
TSC2  Cell growth FBW5 Hs, Dm (Hu et al., 2008) 
SKN-1  Stress response and 
longevity 
WDR23 Ce (Choe et al., 2009) 
ER-a
c
 Estrogen receptor AhR
b
  Hs (Ohtake et al., 2007) 
WDR5
c
 Epigenetic regulation WDR5 Hs (Nakagawa and Xiong, 2011)  
ABI5 Signal transduction DWA1, 
DWA2 
At (Lee et al., 2010a) 
Myc Proto-oncogenic 
transcription factor 
TRPC4AP/ 
TRUSS 
Hs (Choi et al., 2010) 
c-Jun Proto-oncogenic 
transcription factor 
? Hs (Wertz et al., 2004) 
HOXA9 Development ? Hs (Zhang et al., 2003) 
CHK1  Cell cycle checkpoint ? Hs (Leung-Pineda et al., 2009) 
Dacapo Cell cycle inhibitor ? Dm (Higa et al., 2006c) 
Cyclin E Cell cycle  ? Dm (Higa et al., 2006c) 
b-catenin Development ? Hs, Dm (Tripathi et al., 2007) 
RASSF1A Mitosis ? Hs (Jiang et al., 2011) 
STAT1,2,3 Signal transduction        SV5
b,d
 Hs (Andrejeva et al., 2002; Precious et al., 
2005; Ulane and Horvath, 2002; Ulane et 
al., 2005; Ulane et al., 2003) 
UNG2  DNA repair VprBP-
Vpr
d
 
Hs (Ahn et al., 2010; Schrofelbauer et al., 
2005) 
a
Abbreviations for organisms: Hs, Homo sapiens; Xl, Xenopus laevis; Dm, Drosophila melanogaster; Ce: 
Caenorhabditis elegans; Sp: Schizosaccharomyces pombe; At: Arabidopsis thaliana 
b 
Not a WD40 protein 
c 
CUL4B specific 
d
viral protein 
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CRL4 ubiquitylation does not always lead to degradation  
In addition to targeting substrates for proteolytic degradation, CRL4CDT2 can 
promote mono-ubiquitylation on PCNA itself in undamaged cells and cooperates with 
RAD18 to promote translesion DNA synthesis  (Terai et al., 2010).  PCNA ubiquitylation 
seems to be constantly antagonized by the action of ubiquitin-specific protease 1 (USP1) 
and may function to poise cells for repair during DNA replication (Terai et al., 2010).    
Likewise, several studies have observed CRL4DDB2-dependent mono-ubiquitylation of 
core histones (Wang et al., 2006; Guerrero-Santoro et al., 2008; Kapetanaki et al., 2006) 
that have been suggested to function as a signal for the binding of repair factors to 
damaged DNA.  From a biochemical standpoint, it remains unclear how one E3 ligase 
apparently causes monoubiquitylation of some substrates and polyubiquitylation of 
others that leads to degradation.  Further complicating matters, CRL4DDB2 has been 
suggested to also promote non-proteolytic polyubiquitylation of XPC during DNA repair 
(Kapetanaki et al., 2006).  It will be important to determine how different ubiquitin lysine 
residues are linked on different substrates, whether ROC1 can itself switch between 
different E2s or if additional factors that control the ROC1–E2 binding yield such a 
diverse set of ubiquitylated substrates.  
 Though not all CRL4 substrates identified to date are associated with chromatin, 
(as illustrated by the ubiquitylation of cytoplasmically localized TSC2 (tuberous sclerosis 
2) by CRL4AFBW5 (Hu et al., 2008) and ER-α ubiquitylation by CRL4BAhR (Ohtake et al., 
2007)), the majority of the literature on CUL4 complexes supports essential functions in 
DNA repair and replication.  Indeed, VprBP, the focus of my thesis research, is bound to 
chromatin in a cell cycle specific manner, and loss of VprBP in cultured cells causes 
defects in S phase progression (McCall et al., 2008).    However, there is currently no 
clear evidence linking VprBP directly to DNA replication or repair (discussed in detail 
below).   
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Viral Hijacking of DDB1-CUL4  
Many viruses are known to exploit the ubiquitylation pathway to evade innate 
cellular antiviral mechanisms or otherwise benefit viral propagation (Randow and 
Lehner, 2009).  CRL4s are targeted by several viruses including members of the 
paramyxovirus, herpesvirus, lentivirus, and hepadnavirus families.  Although these 
diverse viruses commonly target DDB1, they appear to disrupt CRL4s in different ways.  
Viruses from the paramyxovirus family including simian virus 5, mumps virus and human 
parainfluenza virus type 2, use CUL4–DDB1 to degrade signal transducer and activator 
of transcription (STAT) proteins that respond to interferon signaling and initiate cellular 
antiviral responses (Andrejeva et al., 2002; Ulane and Horvath, 2002).  The crystal 
structure of simian virus 5 V (SV5-V) protein in complex with DDB1 showed that despite 
almost no primary sequence homology with DDB2, SV5-V protein similarly inserts a helix 
between β-propellers  BPA and BPC (Li et al., 2006).   Hepatitis B virus X protein (HBx) 
also binds to DDB1, which is thought to facilitate viral replication (Leupin et al., 2005; 
Leupin et al., 2003) by causing an extended S-phase (Martin-Lluesma et al., 2008).  
Binding assays show that SV5-V and HBx bind DDB1 in a mutually exclusive manner 
(Leupin et al., 2003). Furthermore, structural analysis revealed that HBx, as well as SV5-
V contains primary sequence homology to DDB2’s helix h1 that inserts into a cavity 
formed by BPA and BPC in DDB1 (Scrima et al., 2008). Collectively, these structural 
analyses suggest that HBx and SV5-V viral proteins, although lacking WD40 repeats 
and sharing little primary sequence homology with each other, might form a similar 
structural motif and bind to a region in the BPA-BPC pocket of DDB1 in a manner similar 
to that of DDB2.  The cellular protein(s) targeted by HBx to DDB1–CUL4 ligase remains 
unknown, raising the possibility that HBx facilitates viral propagation by interfering with 
the ubiquitylation of a host protein instead of targeting a novel host protein for 
degradation. This could also be the case for the murine gamma herpesvirus 68 M2 
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protein that binds to CUL4–DDB1, impairs the DNA damage response and inhibits 
apoptosis through unknown cellular mechanisms (Liang et al., 2006).  Most recently, 
several groups have established that HIV-1 Vpr and the related simian 
immunodeficiency virus protein Vpx bind to CRL4VprBP (Belzile et al., 2007; Hrecka et al., 
2007; Le Rouzic et al., 2007; Tan et al., 2007; Wen et al., 2007) (discussed further 
below).  Mechanisms for how CRL4 is exploited by so many divergent viruses remain to 
be shown in detail, but clearly this family of broadly expressed ubiquitin ligases is an 
attractive target.   
 
HIV1 Vpr Binding Protein, VprBP 
VprBP (also known as DDB1-Cullin 4 associate factor, DCAF1) was first 
identified as the HIV1 viral protein r binding protein (Zhang et al., 2001; Zhao et al., 
1994).  HIV1 viral protein r (Vpr) is an accessory protein that is not required for viral 
replication in vitro, but is highly conserved in HIV1, HIV2, and the related simian 
immunodeficiency virus.  Vpr is associated with multiple functions in vivo including 
inducing a G2 cell cycle arrest, promoting apoptosis, and nuclear transport of 
preintegration complexes (Le Rouzic and Benichou, 2005).  Vpr is a multifunctional 
protein and associates with a number of host proteins such as uracil DNA glycosylase 
(UNG2), CDC25, adensosine nucleotide translocator (ANT), and Vpr binding protein 
(VprBP).  A number of long-term nonprogressor patients, individuals who are HIV 
positive but experience extremely slow progression to AIDS even in the absence of 
antiretroviral treatment, have been found to have mutations in Vpr (Rodes et al., 2004).  
Recently, a long-term nonprogressor patient-derived point mutant in Vpr (Q65R) was 
identified to abolish binding with VprBP, suggesting that this association may be 
important for disease progression (Jacquot et al., 2009). 
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Vpr has been reported to arrest infected cells in the G2 phase of the cell cycle by 
activating atacia telengiectasia and Rad3-related protein kinase (ATR).  Vpr does not 
appear to trigger ATR by causing double strand breaks in DNA, but may cause stalled 
replication forks (Lai et al., 2005; Zimmerman et al., 2006).  Vpr associates with VprBP 
in the context of CRL4VprBP (Belzile et al., 2007; Hrecka et al., 2007; Le Rouzic et al., 
2007; Tan et al., 2007; Wen et al., 2007). Studies by several groups demonstrated that 
RNAi-mediated knockdown of Vprbp or Ddb1 mRNA relieves the G2 arrest caused by 
Vpr overexpression (Belzile et al., 2007; DeHart et al., 2007; Hrecka et al., 2007; Le 
Rouzic et al., 2007; Tan et al., 2007; Wen et al., 2007), though observations from our lab 
suggest a caveat to these experiments is that knockdown of Vprbp alone can induce a 
partial G1 arrest.   
Vpr may function to hijack the CRL4VprBP complex to degrade UNG2, a uracil 
DNA glycosylase that removes uracil from DNA as part of the base excision repair 
pathway (Ahn et al., 2010)(Figure 1.3B).  Vpr expression was shown to increase the 
degradation of UNG2, and knockdown of DDB1 or CUL4A/B stabilized UNG2 in the 
presence of Vpr (Schrofelbauer et al., 2007; Wen et al., 2007).  More recently, in vitro 
ubiquitylation of UNG2 by CRL4 and a fragment of VprBP containing residues 987–1396 
was demonstrated (Ahn et al., 2010).  However, it remains unclear whether UNG2 is the 
sole target of CRL4VprBP-Vpr or if additional targets are exploited to benefit HIV 
propagation.  Furthermore, depletion of CUL4 or DDB1 had no effect on UNG2 
degradation in the absence of Vpr (Schrofelbauer et al., 2007; Wen et al., 2007; Ahn et 
al., 2010) indicating that CRL4VprBP cannot ubiquitylate UNG2 in the absence of Vpr.  The 
normal physiological substrate(s) for CRL4VprBP are currently unknown. 
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Figure 1.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Schematic of VprBP.   
 
(A) Schematic of VprBP protein structure.  VprBP is a 1507 amino acid protein that 
contains an alpha-helical LisH domain, a WD40 domain containing two WDXR motifs 
and five additional WD40 motifs, and an acidic residue rich tail.  The N-terminal portion 
of VprBP contains no known protein motifs 
 
(B) VprBP is a component of a CUL4 ubiquitin ligase complex.  VprBP binds to CUL4A 
through the adaptor protein DDB1.  Though no substrate has been identified in for 
CRL4VprBP in normal cells, the uracil DNA glycosylase UNG2 has been proposed to be 
targeted by the complex in the presence of HIV-1 viral protein R (Vpr).
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VprBP was identified in the Xiong lab by former graduate student Chad McCall 
(McCall et al., 2008).  VprBP function as a substrate recruiting receptor for CRL4 is 
inferred from binding with the CUL4-DDB1-ROC1 complex and the presence of the two 
WDXR motifs which are shared in other experimentally demonstrated CRL4 substrate 
receptors.  Thus far, only one candidate substrate, the neurofibromatosis type 2 (NF2) 
tumor suppressor gene product, Merlin, has been reported to be targeted by CRL4VprBP 
ligase for degradation (Huang and Chen, 2008).  However, this finding has been 
seriously challenged by more recent data from the Giancotti lab which suggests that 
Merlin instead functions as an upstream regulator of VprBP (Li et al., 2010b) (discussed 
further in Chapters 3).   
Without any known substrate, the in vivo function of CRL4VprBP remains obscure, 
but a possible function in replication has been proposed.  Knocking down VprBP 
resulted in defective progression through S phase and inhibited proliferation (McCall et 
al., 2008; Hrecka et al., 2007), indicating that VprBP is required for normal cell cycle 
progression in cultured cells.  Furthermore, genetic disruption of Vprbp in mice, 
Drosophila or Arabidopsis caused early embryonic lethality (McCall et al., 2008; Tamori 
et al., 2010; Zhang et al., 2008), indicating that Vprbp is an essential gene.    
The goal of my research has been to explore the in vivo function and mechanism 
of VprBP through a combination of biochemical and genetic approaches.  In chapter 2, I 
describe research testing a hypothesis that VprBP functions in epigenetic modification of 
histones in a manner analogous to the CRL4DDB2 complex.  Intriguingly, I observed a 
possible role for VprBP in histone H4 ubiquitylation.  In chapter 3, I focused on analyzing 
conditional Vprbp mouse embryonic fibroblasts (MEFs) and found that VprBP is required 
for MEF proliferation.  Unexpectedly, I also discovered that high levels of VprBP protein 
are associated with quiescent cells, suggesting functions beyond proliferation.  In 
Chapter 4, I describe data (which has been submitted to the journal Molecular and 
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Cellular Biology for publication) examining temporally controlled disruption of conditional 
Vprbp in mice using the tamoxifen-inducible, Ubiquitin C promoter driven Cre-ERT2.  
This approach allowed me to probe Vprbp function in an unbiased manner to explore 
phenotypes beyond early embryonic lethality and uncovered a role for Vprbp in the 
proliferation and survival of lymphocytes.   Finally, Chapter 5 provides a perspective on 
outstanding questions in VprBP research and discusses potential experiments to 
address these issues.
     
CHAPTER II 
 
BIOCHEMICAL ANALYSIS OF VPRBP IN HISTONE MODIFICATION 
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Summary 
 Epigenetic modifications are critical for normal development, regulation of gene 
transcription, DNA replication and DNA repair.  Known post-translation modifications of 
histones include phosphorylation, acetylation, methylation, sumolyation, and 
ubiquitylation.  The CUL4ADDB2 complex specifically associates with damaged DNA and 
ubiquitylates histones, among other substrates, to mediate the DNA damage response.  
In addition, the Xiong lab previously demonstrated that VprBP specifically binds to 
chromatin.  Based on these observations, we hypothesized that VprBP may function to 
ubiquitylate histones.  I found that loss of VprBP or DDB1 in HeLa cells decreased global 
levels of ubiquitylated histone H4 but not other core histones.   Site-directed 
mutagenesis experiments failed to identify a single lysine residue in histone H4 that is 
ubiquitylated by VprBP, suggesting that multiple residues may be targeted.   
Furthermore, I found that loss of VprBP resulted in an increase in ubiquitylation of the 
linker histone H1.1 suggesting a cross-talk between histone modifications.  These data 
support a role for VprBP in regulating epigenetic modification and suggest that CRL4VprBP 
may regulate a novel ubiquitylation event on histone H4.      
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Background 
To condense the massive amount of DNA in eukaryotic genomes, DNA is 
organized into chromatin fibers.  The fundamental unit of chromatin is the nucleosome, 
which consists of 147 base pairs of DNA wrapped around a histone octomer containing 
two copies each of H2A, H2B, H3, and H4 (Bhaumik et al., 2007).   Additional linker 
histones, such as histone H1, are required to form higher order chromatin structures.  
Regulation of processes involving chromatin dynamics, such as replication, repair and 
transcription, rely on post-translational modifications of histones.  Each core histone has 
a central globular domain, which contains the histone fold required for interactions 
between histones and histone-DNA interactions, as well as N-terminal and C-terminal 
tails.  Post-translational modifications of histones have been observed in the tails as well 
as the globular domain, though the N-terminal tails have the best-characterized 
modifications.  Histones are modified by phosphorylation, acetylation, methylation, ADP 
ribosylation, sumoylation, and ubiquitylation and are highly regulated by enzymes that 
add and remove these modifications (Kouzarides, 2007).   In this chapter, I focus on the 
role that histone ubiquitylation plays in regulating chromatin dynamics.  
In mammalian cells, ubiquitylated histone H2B is associated with active 
transcription, whereas ubiquitylated H2A has been well-studied in both gene repression 
and DNA repair (Groth et al., 2007; Minsky et al., 2008).  H2B is predominately 
ubiquitylated at lysine 120 by BRE1/RNF20 and requires RAD6 as its E2 ubiquitin 
conjugating enzyme (Kim et al., 2009; Kim et al., 2005).  H2B ubiquitylation does not 
appear to be required for transcription, but rather is proposed to be a consequence of 
transcription; H2B ubiquitylation may help to reassemble nucleosomes after the passage 
of the transcriptional apparatus (Fleming et al., 2008; Kim et al., 2009).  H2A is 
ubiquitylated at K119 by the transcripitionally repressive Polycomb complex (PRC1), and 
by several ubiquitin ligases at sites of DNA damage, including Ring2, RNF8 and 
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CRL4DDB2 (Bergink et al., 2006; Huen et al., 2007; Kapetanaki et al., 2006; Kolas et al., 
2007; Wang et al., 2004).  In response to double-strand breaks, H2A is ubiquitylated by 
RNF8 and this ubiquitylation is required for the subsequent recruitment of checkpoint 
proteins BRCA1 and 53BP1.  Both Ring2 and CRL4DDB2 have been shown to ubiquitylate 
H2A following UV damage, but for Ring2, this appears to occur after the assembly of the 
nucleotide excision repair factors as H2A could not be ubiquitylated in several cell lines 
deficient for nucleotide excision repair proteins (XP-A, XP-C, XP-G, and XP-F) (Bergink 
et al., 2006).  The polycomb complex PRC1 contains two ubiquitin ligase subunits, Ring1 
and Ring2.  Both are genetically required during development to repress Hox genes (del 
Mar Lorente et al., 2000; Suzuki et al., 2002), but Ring2 appears to directly ubiquitylate 
H2A whereas Ring1 may function to enhance the catalytic activity of Ring2 (Cao et al., 
2005; Wang et al., 2004).   Intriguing new data suggest that Ring2 may function as part 
of the PRC1 complex in ubiquitylating H2A in both transcriptional repression and DNA 
repair (Ismail et al., 2010).  Less is known about ubiquitylation of histones H3 and H4.  
However, recent evidence suggests that H3 may be ubiquitylated by the RAG1 complex 
during V(D)J recombination (Jones et al., 2011) and that H4 is ubiquitylated in response 
to DNA damage (Yan et al., 2009).   
CRL4DDB2 has been reported to ubiquitylate histone H3 and H4 (Wang et al., 
2006) as well as H2A (Guerrero-Santoro et al., 2008; Kapetanaki et al., 2006) following 
ultraviolet irradiation.  We collaborated with the Zhang lab in demonstrating a function for 
CRL4DDB2 in histone ubiquitylation; CRL4DDB2 was biochemically purified from nuclear 
fractions based on its histone ubiquitylation activity, and identified by mass spectrometry 
(Wang et al., 2006).  H3 and H4 ubiquitylation were induced by UV, and RNAi depletion 
of DDB1, CUL4A or CUL4B abrogated this UV-induced ubiquitylation of histone H3 and 
H4 in vivo.   Thus, CRL4DDB2 plays a role in mono-ubiquitylating core histones in 
response to UV-induced DNA damage.  Based on our observations that VprBP is 
 30 
 
associated with chromatin in a cell cycle dependent manner and forms a CRLVprBP 
complex, we hypothesized that CRL4VprBP may function to ubiquitylate core histones to 
facilitate cell cycle progression.   
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Experimental Procedures 
Cell culture and plasmids 
 A stable HeLa cell line expressing HA-ubiquitin was previously generated (Wang 
et al., 2006).  Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 10% fetal bovine serum (FBS) and 200 μg/ml hygromyocin B in a 37°C 
incubator with 5% CO2.   
 Plasmids containing the β-globin intron and expressing Flag-tagged histone 
(H2A, H2B, H3, or H4) were kindly provided by Dr. Yi Zhang (Wang et al., 2006).  
Histones H1.1, which contains no introns, was cloned by PCR amplification from 
genomic DNA extracted from WI38 cells using the following primers (all primers are 
listed 5’ to 3’): H1.1F GGATCCATGATGTCTGAAACAGTGCCTCCCG;  
H1.1R CTGAATTTACTTTTTCTTGGGTGCCGC.  PCR products was ligated into pCR-
2.1-TOPO using TA cloning (Invitrogen) and subsequently subcloned into pcDNA3-Flag 
using BamHI and EcoRI.   Plasmids expressing VprBP, DDB1, and DDB2 were 
previously described (He et al., 2006; McCall et al., 2008). 
 
Cell transfection and RNAi 
RNAi oligonucleotides were transfected to HeLa-HA-Ub cells using 
Lipofectamine 2000 according to the manufacturer’s instructions (Invitrogen).  The sense 
sequence for oligonucleotides used to knockdown endogenous gene expression is as 
follows: DDB1 5’ GUUUUUGGCAAUCAACAGGTT 3’, VprBP1 5’ 
UCACAGAGUAUCUUAGAGATT 3’, VprBP2 5’ GAAUACUCUUCAAGAAUGATT 3’, and 
control 5’ ACCUCAAGAAUUUAUUGAATT 3’.  For VprBP knockdown, a pool containing 
VprBP1 and VprBP2 oligonucleotides was used.   Transfection of HeLa-HA-Ub cells with 
pcDNA3-Flag- histone was carried out using a calcium-phosphate buffer 24h following 
RNAi transfection.   
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Mutagenesis 
Lysine residues in histone H4 were mutated individually using the QuikChange 
Site-Directed Mutagenesis kit (Strategene) with the following primers:  
H4K6R GGAATTCTGATGTCTGGCCGCGGTAGGGGCGGGAAGGGTTTG;  
H4K9R CTGATGTCTGGCCGCGGTAGGGGCGGGAAGGGTTTGGGTAAGG;  
H4K13R GGCGGGAAGGGTTTGGGCCGCGGAGGTGCCAAGCGC;  
H4K17R GGTAAGGGGGGTGCCCGTCGACACCGCAAGGTGTTGC;  
H4K21R GGGGGTGCCAAGCGCCACCGCAGAGTACTGCGTGACAACATC;  
H4K32R ATCCAGGGCATCACCCGGCCAGCCATCCGGCGTCTG;  
H4K45R GGCGTGGCGGTGTGAGGCGGATATCTGGTCTGATCTACG;  
H4K60R CGCGGTGTGCTGCGGGTGTTCCTCGAGAATGTGATTCGG;  
H4K78R GTCACCTACACCGAGCATGCCCGGCGCAAGACCGTCAC;  
H4K80R ACCTACACCGAGCATGCCAAGCGCCGGACCGTCACAGCC;  
H4K92R GTGGTCTACGCGCTTCGTCGACAGGGACGCACCCTTTATG. 
 
Cellular lysis, immunoprecipitation and western blot analysis 
Cells were harvested 72h after the RNAi transfection by scraping into phosphate 
buffered saline (PBS).  Cell pellets were subsequently lysed in 1% SDS buffer containing 
50 mM Tris-HCl, pH 7.5 and 0.5 mM EDTA and then boiled for 10 minutes.  Lysates 
were diluted 1:10 in 0.1% NP-40 buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% 
NP-40, 50 mM NaF) and histones were immunoprecipitated using Flag M2 antibody 
(Sigma).  Proteins were resolved by SDS-PAGE and immunoblotted using Flag M2, Flag 
M2-HRP (both Sigma), HA 12CA5 (Boehringer-Mannheim) or HA-HRP (Roche). 
For chromatin isolation, cells were lysed in CSK buffer (10 mM PIPES-KOH, pH 
6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 0.5 mM phenylmethylsulfonyl 
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fluoride, 1 mM glycerophosphate, 50 mM NaF, 1 mM Na3VO4, and protease inhibitors) 
containing 0.5% Triton X-100 as described (Cook et al., 2004).  Portions were reserved 
(whole-cell extracts) prior to fractionation by low-speed centrifugation. Detergent-
insoluble pellets were treated for 5 min with 15 U of micrococcal nuclease (Roche) in 
CSK buffer supplemented with 2 mM CaCl2 and then separated again by centrifugation. 
Proteins in the nuclease-soluble fractions of these digests were defined as chromatin 
bound. 
 
Cell Cycle Synchronization and Flow Cytometry 
 Cells were synchronized by double thymidine treatment.  In brief, subconfluent 
HeLa-HA-Ub cells were treated with 2mM thymidine (Sigma T1895) for 16h and then 
released into fresh medium for 8h.  Cells were retreated with 2mM thymidine for 16h, 
released into fresh medium and collected at the indicated time points after release.  
To analyze the cell cycle at each timepoint after release from synchronization, 
cells were fixed in 75% ethanol overnight at 4°C, washed once in 1× PBS plus 1% FBS, 
and then permeabilized in 1× PBS, 0.1 mg/ml RNase A, and 0.1% Triton X-100. The 
fixed and permeabized cells were stained with 50 μg/ml PI and analyzed on a CyAN 
(Dako Cytomation) flow cytometer.  Data were analyzed using Summit software, version 
4.3 (Dako Cytomation). 
 
DNA Damage Induction 
HeLa-HA-Ub cells were treated with 25 J/m2 ultraviolet radiation (UV) 10 minutes prior to 
cell lysis.  Alternatively, HeLa-HA-Ub cells were treated with 25 M etoposide for 4h prior 
to cell lysis. 
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Results 
VprBP may regulate global levels of histone ubiquitylation. 
 To test the possibility that VprBP regulates ubiquitylation of core histones, we 
overexpressed Flag-tagged versions of the four major core histones in a stable HeLa cell 
line which expresses HA-ubiquitin (HeLa-HA-Ub) following RNAi for VprBP, DDB1 or 
control.  Cells were lysed in 1 % SDS lysis buffer and boiled to disrupt chromatin, and 
lysates were immunoprecipitated with anti-Flag antibody. An apparent ubiquitylated H4 
was observed in control cells, but not in cells knocked down for DDB1 or VprBP, 
suggesting that CRL4VprBP targets H4 for ubiquitylation (Fig. 2.1).  H4 ubiquitylation has 
been scarcely reported, but has been reported in response to UV- and doxorubicin-
induced DNA damage (Wang et al., 2006; Yan et al., 2009).  Our preliminary results 
suggested that VprBP may play a role in H4 ubiquitylation. 
 
VprBP promotes H4 modification, but inhibits H1.1 modification. 
In addition to examining the role of VprBP in core histone ubiquitylation, we also 
asked whether VprBP might also affect the ubiquitylation of linker protein histone H1.1.  
As in the previous experiment, HeLa-HA-Ub cells were treated with RNAi oligos to 
VprBP, DDB1 or control and subsequently transfected with pcDNA3-Flag-Histone or 
pcDNA3-GFP plasmids.  The efficiency of RNAi and equal loading was determined by 
western blotting of input cellular lysate. Following immunoprecipitation by Flag antibody, 
we examined the ubiquitylation of histone proteins by first probing for ubiquitin by 
western blotting for HA.  We detected a ubiquitin band corresponding to ubiquitylated 
H2A in control cells and siVprBP cells, which verified that our assay worked as expected 
and established that VprBP plays no role in H2A ubiquitylation.  No additional proteins 
were detected upon probing for ubiquitin.  After striping the membrane and re-probing for 
histone proteins with Flag-HRP antibody, we detected all 5 histone proteins, and a  
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Figure 2.1 
 
 
 
 
 
 
 
 
 
Figure 2.1.  VprBP regulates global levels of H4 ubiquitylation. 
A stable HeLa cell line expressing HA-ubiquitin (HeLa-HA-Ub) was transfected with 
pcDNA3-Flag-Histone or pcDNA3-GFP plasmids as indicated 24 hours following RNAi 
treatment.  Cells were lysed in 1% SDS buffer and boiled.  Histone proteins were 
immunoprecipitated from lysate using Flag antibody, resolved by SDS-PAGE and 
immunoblotted with Flag antibody.  An apparent ubiquitylated H4 was observed in 
control cells, but not in cells knocked down for DDB1 or VprBP. 
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Figure 2.2 
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Figure 2.2. VprBP promotes H4 modification, but inhibits H1.1 modification. 
 
HeLa-HA-Ub cells were treated with RNAi oligos to VprBP, DDB1 or control as indicated 
and subsequently transfected with pcDNA3-Flag-Histone or pcDNA3-GFP plasmids as 
indicated.  Histone proteins were immunoprecipitated from lysate using Flag antibody 
and resolved by SDS-PAGE.  RNAi efficiency was confirmed by immunoblotting for 
VprBP and DDB1.  The lower panel of the membrane was first blotted with HA-HRP, and 
detected ubiquitylated-H2A in control and siVprBP treated cells.  The membrane was 
then stripped and probed with Flag-HRP.  An increase in H1.1 modification and a 
decrease in H4 modification were observed following siVprBP treatment. 
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slower migrating form of histones H1.1, H2A, and H4.  As was seen previously, loss of 
VprBP corresponded with loss of modified H4 protein.  In addition, we now observed that 
loss of VprBP, and to a lesser extent, DDB1 depletion, correlated with an increase of 
modified histone H1.1.  This unexpected result indicates that CRL4VprBP indirectly 
impacts the modification of histone H1.1 and suggests the possibility that there is cross-
talk between H4 modification and H1.1 modification.   
The fact that the modified version of both H1.1 and H4 were not detected by HA 
immunoblotting suggests one of two possibilities: (1) the level of modified histone was 
below the detection threshold for the HA antibody, but not for the highly sensitive Flag 
M2 antibody, or (2) the histone proteins have a post-translational modification which 
does not contain ubiquitin.  Indeed sumoylated H4 has been noted in both S. cerevisiae 
and human cells using a system similar to ours, i.e. overexpression of Flag-tagged H4 
and HA-tagged SUMO.  However, SUMO, a ubiquitin-like protein with an apparent 
molecular weight of 15 kDa, runs at a significantly higher molecular weight than 
ubiquitin, which is 8.5 kDa; HA-sumoylated conjugated Flag-H4 migrates slower than 
antibody light chain  while HA-ubiquitin conjugated Flag-H4 migrates faster than light 
chain (see (Shiio and Eisenman, 2003)).  This suggests, but does not prove, that the 
level of HA-ubiquitylated H4 is below the detection limit of the HA antibody.  Despite 
extensive efforts to scale up or modify the protocol (e.g. immunoprecipitate with HA 
antibody followed by Flag western blot), I was unsuccessful at positively identifying 
ubiquitylated H4 (data not shown).  Thus I refer to this slower migrating form of H4 as 
modified rather than ubiquitylated. 
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 H4 modification is potentially dependent on cell cycle phase. 
To determine the biological significance of H4 modifications, I sought to 
determine cellular conditions which promoted ubiquitylation.  Because VprBP binding to 
chromatin is cell cycle dependent, I hypothesized that if H4 ubiquitylation depended on 
VprBP, modification should also occur in a cell cycle-dependent manner.  To test this 
idea, I synchronized HeLa-HA-Ub stable cells at the G1-S boundary using a double 
thymidine block following transfection with pcDNA3-Flag-H4 and collected at 0, 2, 4, 8, 
12h after release.  A 10 cm dish was used for each time point and cells collected were 
divided into two fractions: (1) cells were fixed with ethanol for flow cytometry, and (2) 
cells were lysed in SDS buffer and immunoprecipitated with Flag antibody.  Flow 
cytometric analysis of propidium iodide stained cells demonstrates the cell cycle phase 
and synchrony of each time point (Fig. 2.3A).  Input lysate for immunoprecipiation from 
each time point was resolved by SDS-PAGE, and immunoblotted for VprBP.  Total 
VprBP showed a cell cycle-dependent  expression pattern with low levels at the onset of 
S-phase and increasing protein levels through G2-phase (Fig. 2.3B and in agreement 
with (Maddika and Chen, 2009)).  In addition, I examined the status of H4 modification, 
and observed very low levels of modified H4 in G2 phase cells at 8 and 12 h following 
release (Fig. 2.3B).  This observation is consistent with a role for CRL4VprBP in modifying 
histone H4.  These data also highlights the difficulty of detecting modified H4, suggesting 
that this modification is not very abundant or is readily lost during cell lysis, perhaps due 
to highly active deubiquitylase enzymes.   
 
H4 modification and VprBP binding to chromatin is not induced by DNA damage. 
To further probe for potential biological functions for VprBP-induced H4 
modification, I tested if VprBP binding to chromatin or H4 modification can be induced by 
DNA damage.  For DNA damage agents, I tested ultra-violet irradiation (UV), which 
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induces pyridimine dimers and (6-4) photoproducts, and etoposide, a topoisomerase II 
inhibitor which induces double and single strand DNA breaks.  In contrast to published 
results (Wang et al., 2006), I did not see an increase in H4 ubiquitylation in response to 
UV treatment (Fig. 2.4A).  Furthermore, I did not observe an increase in VprBP binding 
to chromatin in response to UV whereas DDB1 and CUL4A association with chromatin 
increased in response to UV (Fig. 2.4B) (consistent with (McCall et al., 2008)).  This test 
serves as a positive control for UV treatment.  In addition, I did not observe any increase 
in H4 ubiquitylation in response to etoposide-induced DNA damage, nor any increased 
association of VprBP, DDB1 or CUL4A with chromatin (Fig. 2.4A and 2.4B), indicating 
that CRL4AVprBP is not involved in mediating DNA damage response after etoposide-
induced DNA breaks.  Cumulatively, these results indicate that CRL4VprBP and histone 
H4 modification are not involved in the response to UV- or etoposide-induced DNA 
damage. 
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Figure 2.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. H4 modification is potentially dependent on cell cycle phase. 
 
HeLa-HA-Ub cells transiently transfected with pcDNA3-Flag-H4 were synchronized at 
G1-S using a double thymidine block.  (A) Flow cytometric analysis was used to verify 
synchronization at each time point collected.   
 
(B) Whole cell lysate of a portion of synchronized cells was obtained, resolved by SDS-
PAGE, and immunoblotted.  A final portion of cells was lysed, immunoprecipated using 
Flag antibody, resolved by SDS-PAGE and immunoblotted with Flag antibody to detect 
histone H4. 
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Figure 2.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F 
Figure 2.4.  H4 modification and VprBP binding to chromatin is not induced by 
DNA damage. 
 
(A) H4 ubiquitylation does not increase in response to UV or etoposide.  HeLa-HA-Ub 
cells were transfected with pcDNA3-Flag-H4 as indicated and treated with 25 J/m2 UV 
(10 min) or 25 M etoposide (4 h) as indicated.   
 
(B)  VprBP association with chromatin is not increased in response to DNA damage.  
HeLa cells were treated with UV or etoposide as indicated.  Cells were lysed in CSK 
buffer, and the chromatin fraction was isolated.  As a positive control, DDB1 binding to 
chromatin increases in response to UV treatment.  
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Mutagenesis of H4 indicates multiple sites affect H4 modification. 
Several known post-translational modifications occur on the N-terminal tail of H4 
(Fig. 2.5B).  To better understand the nature of the histone H4 modification observed in 
this study, I sought to identify which residue on H4 was modified.  Post-translational 
modification by both ubiquitin and SUMO require covalent conjugation to a lysine residue 
within the substrate protein.  To determine which lysine is modified in H4, I individually 
mutated every lysine residue in histone H4 in both the N-terminal tail and the globular 
domain (K5, K8, K12, K16, K20, K31, K44, K59, K77, K79, K91) and substituted lysine 
with arginine by site-directed mutagenesis.  After transient transfection into HeLa-HA-Ub 
cells, cells were lysed, Flag-H4 protein was immunoprecipitated, resolved by SDS-PAGE 
and detected by immunoblotting for Flag (Fig. 2.5).  Surprisingly, I found that no single 
mutation completely abolished H4 modification.  Typically mono-ubiquitylated or 
sumoylated proteins have a specific lysine residue which is targeted by modification.  
That lysine mutation did not disrupt H4 modification suggests that H4 can be mono-
ubiquitylated (or sumoylated) at more than one residue. 
 
VprBP does not readily bind core histones. 
Observations that H4 modification correlated with previously-established timing 
of VprBP binding to chromatin suggested that VprBP may directly ubiquitylate H4.  To 
test this possibility, Flag-H4 and Myc3-VprBP were transiently transfected into 293T cells 
and binding was probed by immunoprecipatation after micrococcal nuclease digestion.  
As a positive control, Flag-H2A and DDB2 were also co-expressed in 293T cells.  As a 
negative control, Myc3-VprBP was overexpressed with Flag-H2A.  Overexpression of 
DDB2 clearly increased the level of ubiquitylated H2A, and DDB2 could be detected in 
the Flag-H2A immunoprecipitation, though H2A was not detected in the reciprocal 
immunoprecipitation (Fig. 2.6).  This finding is consistent with published results that 
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CRL4DDB2 ubiquitylates histone H2A (Guerrero-Santoro et al., 2008; Kapetanaki et al., 
2006).  However, overexpression of VprBP had no effect on H4 ubiquitylation (Fig. 2.6).  
In addition, VprBP and H4 did not co-immunoprecipate.  While it remains formally 
possible that active DUB activity prevented detection of ubiquitylated H4 and that binding 
between H4 and VprBP is too transient to be detected by immunoprecipitation, the most 
parsimonious explanation is that VprBP does not directly affect H4 modification.   
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Figure 2.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5.  Mutagenesis of H4 indicates multiple sites affect H4 modification. 
 
(A) Lysine residues in histone H4 were substituted with arginine using site-directed 
mutagenesis.  pcDNA3-Flag-H4 constructs were transfected into HeLa-HA-Ub cells; 
cells were subsequently lysed, immunoprecipitated with Flag antibody, resolved by SDS-
PAGE and immunoblotted with Flag to detect H4.   
 
(B) Schematic of histone H4 highlighting known post-translation modifications in the N-
terminal tail region. 
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Figure 2.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. VprBP does not stably bind core histone H4. 
 
293T cells were transiently transfected as indicated.  Cells were lysed in CSK buffer 
containing micrococcal nuclease and subsequently immunoprecipitated for histone 
(Flag) or DWD protein (Myc).  5% inputs and immunoprecipitates were resolved by SDS-
PAGE and immunoblotted as indicated. 
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Discussion 
 The experiments described in this chapter provided evidence that VprBP 
positively regulates modification of H4.  The initial experiments were designed to detect 
ubiquitylation of histone proteins, though I was ultimately unable to definitively determine 
the identity of the modification.  The size of the mobility shift, however, suggests that H4 
is modified by ubiquitin in this assay rather than SUMO.  Furthermore, I was not able to 
identify a specific lysine residue on H4 which was modified.  These data suggest the 
possibility that H4 can be modified at more that one lysine residue.  Throughout these 
studies, I had difficulties consistently detecting H4 ubiquitylation, suggesting that it is a 
rare event which is difficult to detect using the described methods.   Attempts to identify 
biologically relevant conditions which enhanced H4 ubiquitylation suggested that H4 
modification may increase in the G2-phase of the cell cycle, but did not increase in 
response to UV-treatment or etoposide treatment.  This observation is particularly 
surprising given that H4 ubiquitylation by BBAP (B-lymphoma and BAL-associated 
protein) E3 ubiquitin ligase was reported in response to the topoisomerase II inhibitor 
doxorubicin  (Yan et al., 2009).  This discrepancy could suggest that the dose of 
etoposide used in my study was insufficient, or that doxorubicin is more potent at 
inducing H4 ubiquitylation.  In the study by the Ship lab, depletion of BBAP delayed the 
recruitment of 53BP1 to sites of DNA damage whereas overexpression of BBAP 
increased H4 ubiquitylation in vivo (Yan et al., 2009).  Given that I was unable to detect 
any increase in H4 ubiquitylation upon VprBP overexpression, I conclude that VprBP at 
best plays an indirect role in H4 ubiquitylation.  This result is in contrast to my positive 
control which showed that DDB2 overexpression increased the ubiquitylation of H2A.   
 What is the role of core histone ubiquitylation in response to DNA damage?  In 
the case of H4, ubiquitylation was suggested to trigger H4K20 methylation by PR-
SET7/SET8 and 53BP1 recruitment to DNA damage (Yan et al., 2009).  H2A 
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ubiquitylation by RNF8 also seems to trigger recruitment of repair factors such as 53BP1 
and BRCA1 in response to double strand breaks (Mailand et al., 2007, Huen, 2007 
#2255).  My data, as well as studies by the Levine lab, support a role for CRL4DDB2 in 
H2A ubiquitylation; DDB2-induced ubiquitylation was likewise suggested to function as a 
signal for the binding of repair factors to damaged DNA (Guerrero-Santoro et al., 2008; 
Kapetanaki et al., 2006).   
The view that CRL4DDB2 promotes the binding of other factors to the lesion is 
challenged by evidence that loss of CRL4DDB2 activity enhances rather than inhibits DNA 
repair in cells lacking Cul4A (Liu et al., 2009).  In addition to losing CRL4DDB2 function 
toward H2A, DDB2 itself was accumulated following loss of Cul4A (Liu et al., 2009).  
Perhaps, ubiquitylation of DDB2 functions to restrict repair activity to the damaged DNA 
lesion instead of spreading to undamaged DNA.  In the case of CRL4VprBP, I suggest that 
this ubiquitin ligase is upstream of pathways that control H4 ubiquitylation, rather than 
serving as the direct E3 ubiquitin ligase for H4.  It will be interesting to see if CRL4VprBP 
has any function in positively regulating BBAP and whether this regulation might account 
for the change in H4 modification observed in these studies. 
 
     
CHAPTER III 
 
ANALYSIS OF VPRBP DISRUPTION IN MOUSE EMBRYONIC FIBROBLASTS 
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Summary 
VprBP, a WD40 domain-containing protein that binds to the DDB1-CUL4-ROC1 ubiquitin 
ligase, is required for cellular proliferation in immortalized cell lines and is required for 
embryonic development in mice.  Merlin, a FERM-domain protein which represses 
growth in response to contact inhibition, was reported as a substrate for CRL4VprBP.  To 
further investigate the role of Vprbp in cellular proliferation, I disrupted Vprbp using a 
conditional allele in mouse embryonic fibroblasts (MEFs) and characterized these cells.  
I found that VprbpD was not a true null-allele, as small levels of a truncated VprBP 
protein were detected following Cre-mediated recombination.  However, MEFs with 
VprbpD failed to proliferate, and were phenotypically similar to cultured cells depleted of 
VprBP by RNAi.  I could not confirm a role for CRL4VprBP in Merlin degradation, however 
experiments designed to test this possibility unexpectedly uncovered abundant 
accumulation of VprBP protein in contact-inhibited and serum-starved wild-type MEFs.  
This accumulation was particularly pronounced in MEFs, but not in WI38 or MCF10A 
cells, suggesting this function of VprBP may be developmentally or cell-type regulated.  
Further, conditional disruption of Vprbp in MEFs was incompatible with survival in low-
serum conditions, suggesting that VprBP may be required for quiescent MEFs or for 
tolerance of restrictive growth conditions.     
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Background  
 The Vprbp gene encodes a 175 kDa protein that contains LisH and WD40 
domains, and a negatively charged C-terminal tail.  VprBP was first described as a 
binding partner for the HIV1 Vpr protein (Zhao et al., 1994) and was subsequently noted 
as a transcriptional target of Sox9 (Zhao et al., 2002).  However, its biological function 
remained largely obscure until the identification of VprBP by three independent lab 
groups as part of the CUL4A-DDB1 complex (Angers et al., 2006; He et al., 2006; Jin et 
al., 2006).  VprBP contains two WDXR motifs, but not the larger DWD box sequence, 
and mutation of the conserved arginine residues in both WDXR motifs disrupts binding 
to DDB1.  Through its interaction with DDB1, VprBP binds to CUL4A or CUL4B, 
suggesting that VprBP functions as a substrate receptor for CRL4 complexes.  VprBP, 
like a subset of other substrate targeting receptors, has also been noted to bind the 
COP9 signalosome subunits (Hrecka et al., 2007; McCall et al., 2008; Olma et al., 2009), 
indicating that CRL4VprBP may exist in an unneddylated state until appropriately activated.  
In addition, VprBP complexes contain DDA1 (Hrecka et al., 2007; McCall et al., 2008; 
Olma et al., 2009), a protein of unknown function which associates with several 
chromatin-bound CRL4 complexes.  Recent data indicate that two CRL4VprBP complexes 
may functionally cooperate in ubiquitylation through dimerization of the alpha-helical 
LisH domain of VprBP (Ahn et al., 2011).  Cumulatively, these data provide the basis for 
a working model that the primary biochemical function of VprBP is to function as a 
substrate recruiting receptor for a CRL4-based complex.  However the molecular targets 
and in vivo function of VprBP are still largely unknown.  
VprBP knockdown arrests cell cycle progression in multiple cell lines and in 
primary cells, suggesting that VprBP is required for cellular proliferation (Hrecka et al., 
2007; Li et al., 2010b; McCall et al., 2008).  Overexpressed VprBP is primarily nuclear in 
localization (Li et al., 2010b), and a portion of endogenous VprBP associates with 
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chromatin (Belzile et al., 2010; McCall et al., 2008).  These observations led to 
speculation that VprBP may function in DNA replication or repair.  Indeed, VprBP 
knockdown modestly induced H2AX phosphorylation (Hrecka et al., 2007), but not 
phosphorylation of CHK1/2 (data not shown).  Further, DNA damaging agents did not 
promote binding of VprBP to chromatin (Chapter 2).  Thus any putative contribution of 
VprBP to the DNA repair process remains unclear at the present time. 
To determine the in vivo function of Vprbp in a genetically controlled setting, I 
sought to characterize conditional Vprbp MEFs.  In addition, I tested the model that 
CRL4VprBP promotes Merlin polyubiquitylation and degradation, as reported (Huang and 
Chen, 2008).    Merlin, a tumor suppressor protein first identified in familial cases of 
schwanomas, is encoded by the Nf2 gene (McClatchey and Fehon, 2009).  Mice which 
are heterozygous for Nf2 frequently develop osteosarcoma or a broad spectrum of other 
cancers including lymphoma and lung adenocarcinoma (McClatchey et al., 1998), while 
homozygous deletion of Nf2 results in embryonic lethality around day 6.5 (McClatchey et 
al., 1997).  Merlin has been suggested to mediate contact inhibition and inhibit 
proliferation in low serum by inhibiting a number of signaling pathways including Ras-
ERK and Rac1 (Jung et al., 2005; Kissil et al., 2003; Morrison et al., 2007; Okada et al., 
2005).  The data reported here and elsewhere (Li et al., 2010b) do not confirm a role for 
CRL4VprBP in Merlin degradation, though we can confirm Merlin-VprBP binding.  In 
addition, I found that Vprbp is essential for cellular proliferation in MEFs, and observed a 
massive VprBP protein accumulation in serum-starved or contact-inhibited MEFs.  
These data suggest that VprBP may also play a role in regulating the cellular response 
to contact inhibition and mitogen withdrawal. 
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Experimental Procedures 
Animal maintenance and generation of mouse embryonic fibroblasts 
Generation of the Vprbp conditional allele (Vprbpflox) and Neo allele (Vprbp-) by Dr. Paula 
Miliani de Marval was previously described (McCall et al. 2007).  Mice were backcrossed 
into the C57BL/6 for at least four generations.  Germline transmission of VprbpD was 
obtained by crossing Vprbp conditional mice with EIIA-Cre+ mice (Jackson Laboratories, 
stock 003724).  In addition, Vprbpflox/flox  mice were crossed with Ubc-CreERT2+ mice that 
were generously provided by Dr. Eric Brown (Ruzankina et al., 2007).  Vprbpflox/+;Ubc-
CreERT2+ were intercrossed and mouse embryonic fibroblasts (MEFs) were isolated 
from embryos at day 13.5 post coitus (E13.5). MEFs at early passage (passage 1-5) 
were used for all experiments described.    Where specified, adenovirus-Cre-GFP 
(Vector Biolabs) at MOI 250 was used to transduce VprbpF/- MEFs.   
 
Genotyping 
Primers for genotyping  Vprbp alleles: 5’ CTGGGTAGCTACTGTTGACTACTCACTGCG 
3’, 5’ CAGTTAGAGAGTGACTTTGGACG 3’, and 5’ GCTGCCAACTATGGGTGC 3’, 
which detected 434 bp, 468 bp and 280bp bands for the wild-type, flox and D alleles, 
respectively.    Primers for genotyping Cre-ERT2: 5’ GCTGGAGTTTCAATACCGGAG 3’ 
and 5’ CTTAGAGCGTTTGATCATGAGC 3’.  Il2 primers were included in the CreERT2 
PCR as an internal control: 5’ CTAGGCCACAGAATTGAAAGATCT 3’ and 
5’GTAGGTGGAAATTCTAGCATCATC 3’.  Primers for genotyping Cre for EIIA-Cre+ 
mice: 5’ GCGGTCTGGCAGTAAAAACTATC 3’ and 5’ 
GTGAAACAGCATTGCTGTCACTT 3’.  PCR conditions were as follows: 94ºC for 2 min, 
40 cycles of 94ºC for 1 min, 58ºC for 2 min, and 72ºC for 2 min followed by 72ºC for 5 
min. 
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Cell Culture 
MEFs were cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% 
Fetal Bovine Serum (FBS).  To induce CreERT2 translocation in Ubc-CreERT2+ MEFs, 
1 μM 4-Hydroxytamoxifen (Sigma H7904) was added to the culture medium and cells 
were assayed after 72h.  To serum starve MEFs, cells were cultured in DMEM 
containing 0.1% FBS for 72h.    WI38 cells were cultured in DMEM containing 10% FBS; 
MCF10A cells were cultured in DMEM F12 medium containing 5% Fetal Calf Serum, 20 
ng/ml EGF, 0.05 mg/ml hydrocortisone and 10 mg/ml insulin.   
 
Cell lysis and western blot analysis 
Cells were lysed in 0.1% NP-40 buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% 
NP-40, 50 mM NaF, 1 mM PMSF, 1 mM Na3VO4, and a cocktail of protease inhibitors 
containing 25 mg/L leupeptin, 25 mg/L aprotinin, 150 mg/L benzamidine, and 10 mg/L 
trypsin inhibitor) for co-immunoprecipitation experiments, or in RIPA buffer (50 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% NP-40, 0.5% sodium deoxycholate,  1 mM 
PMSF, 1 mM Na3VO4, 1mM DTT, and a cocktail of protease inhibitors containing 25 
mg/L leupeptin, 25 mg/L aprotinin, 150 mg/L benzamidine, and 10 mg/L trypsin inhibitor) 
for western blot analysis.  Proteins were resolved by SDS-PAGE, transferred to PVDF 
membrane (Millipore) and proteins were probed with the following primary antibodies: 
VprBP (McCall et al. 2007), DDB1 (Zymed laboratories), Merlin (C-19 Santa Cruz), 
Tubulin (Neomarkers), Actin (Santa Cruz), p53 (Novocastra), p21 (Santa Cruz), 
phospho-Rb (Cell Signaling). 
 
Flow Cytometry 
To analyze DNA replication by bromodeoxyuridine (BrdU) labeling, cells were fixed in 
75% ethanol overnight at 4°C. Nuclei were isolated by incubating cells in 0.08% pepsin 
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in 0.1 N HCl for 20 min at 37°C, and then DNA was denatured by incubating cells in 2 N 
HCl for a further 20 min at 37°C. After the HCl was neutralized with 2 volumes of 0.1 M 
sodium borate, pH 8.5, the cells were washed with immunofluorescence assay (IFA) 
buffer (10 mM HEPES [pH 7.3], 150 mM NaCl, 4% FBS, 0.1% sodium azide) plus 0.5% 
Tween-20. The cells were labeled with FITC-conjugated anti-BrdU (BD Biosciences).   
Cells were stained for DNA content by incubation with 0.1 mg/ml propidium iodide in IFA 
buffer containing RNase A. Stained cells were analyzed on a FACScan CyAN (Dako 
Cytomation) flow cytometer, and data were analyzed using Summit software (Dako 
Cytomation).
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Results 
Characterizing VprbpD. 
The Vprbp genomic locus spans approximately 60 kb on mouse chromosome 9 
and contains 24 exons.  Our previous work characterizing loss of Vprbp in mice and 
MEFs utilized a Vprbp- allele which contains a neomycin resistance cassette inserted 
after exon 6 of Vprbp and deletion of exons 7 and 8 (Figure 3.1).  Loss of Vprbp    
(Vprbp-/-) is embryonic lethal prior to day 7.5, necessitating the use of a conditional allele 
to study loss of Vprbp in MEFs.  Our preliminary experiments, led by Dr. Paula Miliani de 
Marval, characterized VprbpF/- MEFs following retroviral transduction of Cre.  To avoid 
possible unintended effects of the neomycin cassette, I characterized VprbpF/F MEFs 
following Cre-mediated recombination.    
The Ubc-CreERT2+ transgenic mice express a 4-OH-tamoxifen (4OHT)-inducible 
Cre driven by the Ubiquitin C promoter and provides a system to conditionally activate 
Cre recombinase in a wide range of tissues upon exposure to 4OHT (Ruzankina et al., 
2007). Use of 4OHT-inducible Cre offers a unique advantage to my study as it avoids 
the potential complication of cell cycle arrest resulting from viral transduction.  To 
optimize conditions for disrupting Vprbp, I treated MEFs with a range of doses of 4OHT 
and lysed cells 60 hours after drug treatment.  I observed a dose-dependent loss of full-
length VprBP, but surprisingly detected low-level expression of a truncated protein by 
immunoblotting with an antibody against the C-terminus of VprBP (Fig. 3.2A).  The 
conditional allele used to disrupt Vprbp contains loxP sites flanking exons 7 and 8, and 
recombination at these sites is predicted to result in a frame-shift and premature stop-
codon should splicing occur between exons 6 and 9 (Fig. 3.2D).  The presence of a 
truncated, in-frame VprBP was therefore unexpected.  I isolated cDNA from 4OHT- 
treated VprbpF/F; CreERT2+ MEFs, 
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Figure 3.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Vprbp genomic locus and alleles.   
 
A schematic of the Vprbp genomic locus on mouse chromosome 9.  Black boxes 
indicate exons; noteworthy protein features of VprBP are indicated above the exons 
which encode them.  The targeting construct incorporated FRP sites (blue) flanking the 
neomycin resistance cassette and LoxP sites (red) flanking exons 7 and 8.  Targeted ES 
cells were treated with Cre recombinase or Flipase to generate Vprbp- and VprbpF, 
respectively, as previously reported (McCall et al., 2008).  Following Cre-mediated 
recombination, VprbpF gives rise to VprbpD, which differs from Vprbp- by the absence of 
the neomycin resistance cassette.     
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amplified the Vprbp transcript by PCR and submitted the gel-purified clone for 
sequencing (Fig. 3.2B).  I found that exons 6 and 9 were spliced in an unconventional 
manner which resulted in an in-frame Vprbp transcript that lacks the coding sequence for 
amino acids 173-375 (Fig. 3.2C & D).  The allele resulting from Cre recombination of 
conditional Vprbp is therefore not a null allele, but rather a hypomorphic allele which we 
have termed VprbpD.   
 
VprbpD is a severe hypomorphic allele. 
To determine if VprbpD/D mice were viable, I crossed VprbpF/F mice with EIIA-Cre+, which 
express Cre under the control of the adenovirus EIIA promoter in a broad range tissues, 
to generate germline transmission of VprbpD.  I found that subsequent intercrosses of 
VprbpD/+ mice produced no viable VprbpD/D  pups (Fig. 3.3A) or embryonic day (E) 12.5 
embryos (data not shown), indicating that homozygous Vprbp disruption causes 
embryonic lethality.  To explore the cellular phenotype of VprbpD/D MEFs, I examined 
cellular proliferation by a growth curve assay (Fig. 3.3B) and BrdU incorporation (Fig. 
3.3D) in 4OHT-treated VprbpF/F; CreERT2+ MEFs and found that disruption of Vprbp 
blocked cell cycle progression, mimicking results reported following VprBP knockdown 
(Hrecka et al., 2007; McCall et al., 2008).  However, unlike previously published results 
for VprBP knockdown in U2OS cells and WI38 cells, I did not detect induction of p53 
following disruption of Vprbp (Fig. 3.3C).  Because VprBP has been established to bind 
chromatin, I tested if the hypomorphic VprBPD protein could bind chromatin by isolating 
the chromatin fraction of MEFs following Cre-mediated recombination.  Though VprBPD 
was apparent in whole cell lysates, I was unable to detect VprBPD on chromatin, 
suggesting that VprBPD cannot functionally compensate for the chromatin-dependent  
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Figure 3.2 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. VprbpD is a hypomorphic allele.   
 
(A) VprbpF/F; CreERT2+ and VprBPF/F mouse embryonic fibroblasts (MEFs) were treated 
with 4-hydroxy-tamoxifen (4OHT).  Cell lysates were resolved by SDS-PAGE and 
immunoblotted with an antibody against the C-terminus of VprBP or a-tubulin.  Low-level 
expression of a truncated protein was noted.   
 
(B) PCR of cDNA from 4OHT-treated VprbpF/F; CreERT2+ and VprBPF/F MEFs using 
primers corresponding to sequences from exons 4 and 11 of Vprbp.   
 
(C) Sequencing data of Vprbp cDNA cloned from 4OHT-treated VprbpF/F; CreERT2+ 
MEFs showing the coding region spanning the exon 6 and exon 9 junction.    
 
(D)  Schematic of exon 6 to exon 9 junction following Cre-mediated recombination of 
conditional Vprbp.  Excision of exons 7 and 8 is predicted to result in a frame-shift and 
premature stop codon.  Shown here is the nucleotide (nt) sequence of the junction 
between exons 6 and 9 and the resulting amino acid (aa) sequence.   
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Figure 3.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.  VprbpD mimics loss of function.   
 
(A) VprbpD/+ mice were intercrossed and the genotype of offspring at postnatal day 21 is 
shown.  ‘Mendelian’ indicates the expected number based on Mendelian inheritance.   
 
(B)  Disruption of Vprbp impairs cell proliferation.  48 h after treatment with 1mM 4OHT, 
equal numbers of MEFs were plated and subsequently counted at the indicated time 
points.  Experiment was performed in triplicate.   
 
(C) Vprbp disruption does not induce p53.  Western blot of cell lysates from MEFs as 
indicated.  Adenovirus-Cre treated MEFs were used as a positive control for disruption of 
Vprbp and induction of p53.   
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(D) Vprbp disruption reduces 5’-bromo-2’-deoxyuridine (BrdU) incorporation.  60h after 
treatment with 1mM 4OHT, MEFs were pulse-labeled with BrdU for 6 h, fixed, stained 
with FITC-conjugated anti-BrdU antibody and propidium iodide, and detected by flow 
cytometry.    
 
(E) VprBPD does not bind to chromatin.  VprbpF/+ or VprBPF/- MEFs were treated with 
Adenovirus-Cre or mock.  Cells were lysed and chromatin fractions were isolated, 
resolved by SDS-PAGE, and immunoblotted as indicated. 
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functions of wild-type VprBP.  Overall, these results demonstrate that VprbpD causes a 
similar cellular phenotype as VprBP knockdown in cultured cells.   
 
Evidence for VprBP accumulation in quiescence. 
I next sought to determine if VprBP regulates Merlin ubiquitylation, as reported 
(Huang and Chen, 2008).  To first verify a relationship between VprBP and FERM-
domain containing protein Merlin, my colleague Dr. Tadashi Nakagawa overexpressed 
wild-type Merlin or the patient-derived L64P point mutant of Merlin in 293T cells (Fig. 
3.4A).  We found that wild-type Merlin, but not L64P, binds with endogenous VprBP and 
DDB1 in agreement with published results (Huang and Chen, 2008; Li et al., 2010b).  To 
determine if VprBP regulated global levels of Merlin in MEFs, I treated VprbpF/F; 
CreERT2+ and VprBPF/F MEFs with 4OHT and examined Merlin by Western blot (Fig. 
3.4B).  I was unable to detect any change in total Merlin protein, despite apparent loss of 
full-length VprBP, suggesting VprBP does not regulate Merlin levels under these 
conditions. 
  Because previous work by the Chen lab indicated that VprBP degrades Merlin 
in response to serum stimulation in HeLa cells, I conducted a time course experiment in 
wild-type MEFs to determine the optimal time point of Merlin degradation in response to 
serum stimulation (Fig. 3.4C).  While I could not see clear evidence for Merlin protein 
loss in response to serum stimulation, I unexpectedly uncovered a dramatic 
accumulation of VprBP protein in serum-starved cells (Fig. 3.4C).  VprBP protein was 
decreased by 16h post-stimulation, which corresponded to phosphorylation of RB at 
serine 807/811.  To verify VprBP accumulation in serum-starved MEFs, I performed the 
reciprocal experiment in which MEFs were cultured in DMEM containing 10% FBS, 
switched to 0.1% FBS-containing medium, and monitored at 12, 24, 36, 48, and 72 
hours after culture in low-serum medium (Fig. 3.4D).  In agreement with the previous 
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Figure 3.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. VprBP accumulates in serum starved MEFs.   
 
(A) VprBP and Merlin interact.  HA-tagged wild-type (WT) Merlin or patient-derived L64P 
mutant were transiently overexpressed in 293T cells.  Immunoprecipitated WT, but not 
L64P, bound endogenous VprBP and DDB1.   
 
(B) Western blot of whole cell lysate from 4OHT treated VprbpF/F and VprbpF/F; 
CreERT2+ MEFs.   Disruption of Vprbp in MEFs did not cause a change in endogenous 
Merlin levels.   
 
(C)  Western blot of whole cell lysate from WT MEFs, which were starved for 3 days and 
stimulated with medium containing 10% FBS for the number of hours indicated.    
 
(D)  VprBP accumulates in WT MEFs in response to serum starvation.  Western blot of 
cell lysates from WT MEFs, which were cultured in normal medium and subsequently 
switched to medium containing 0.1% FBS for the number of hours indicated.   
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experiment, VprBP protein abundantly accumulated 72h after culture in low-serum 
medium.  Further, an increase in VprBP protein was evident as early as 24 hours after 
switching to low-serum medium, suggesting that VprBP protein accumulation correlated 
with exit from the cell cycle.  Cumulatively, these experiments indicate that VprBP 
protein accumulation is induced by serum-starvation of wild-type MEFs.  To determine if 
VprBP protein accumulation was specific to serum-starved cells or if other types of 
quiescent cells have increased VprBP levels, I examined the effects of cell density on 
VprBP.  Wild-type MEFs, which are non-transformed cells that can be cell-cycle arrested 
in response to contact inhibition, were plated at low, medium and high density (Fig. 3.5).  
Western blotting indicated that VprBP protein levels were elevated when plated at 
increasingly higher density, as was also seen for Merlin protein.  This suggests that 
accumulated VprBP protein in highly confluent MEFs does not function to promote 
proteolytic degradation of Merlin.  Further, this supports a model that VprBP protein 
accumulates in quiescent cells. 
To test if VprBP accumulation is specific to MEFs or is broadly observed in 
multiple cell types, I tested if VprBP accumulates in response to serum starvation or high 
density in WI38 and MCF10A cells.   WI38 cells are a non-transformed, diploid cell line 
derived from normal embryonic lung fibroblasts which can undergo replication-induced 
senescence.  MCF10A is also a non-transformed, diploid cell line which was derived 
from normal breast epithelium and is known to exhibit contact inhibition of cell 
proliferation.  I found that VprBP protein levels were elevated in response to increasing 
cell density in both WI38 and MCF10A cells (Fig. 3.6A and 3.6C), though to a lesser 
extent than observed in WT MEFs.  In contrast to observations in MEFs, serum 
starvation of WI38 or MCF10A cells resulted in very little increase in VprBP protein 
levels.  This result suggests that while VprBP protein accumulation in response to 
contact inhibition is conserved, VprBP accumulation following serum-starvation may vary 
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 Figure 3.5 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. VprBP accumulates in highly confluent MEFs.   
 
WT MEFs were cultured at low, medium, and high density, as shown in phase contrast 
images, for 16 h in DMEM containing 10% FBS.  Cell lysates were resolved by SDS-
PAGE and immunoblotted for VprBP, Merlin and Actin. 
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Figure 3.6 
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Figure 3.6. Accumulation of VprBP is dependent on cell type.   
(A)  WI38 cells were cultured at a range of densities or at medium density ± serum for 
three days.   
 
(B) Phase contrast images of the WI38 cells used for the density experiment in (A).   
 
(C)  MCF10A cells were cultured at a range of densities or at medium density ± serum 
for three days.   
 
(D) Phase contrast images of the MCF10A cells used for the density experiment in (C).   
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between cell lines.  Further, MEFs appear to be the most sensitive system for detecting 
VprBP accumulation following serum starvation or contact inhibition, suggesting a 
possible developmental regulation of this response. 
To determine if VprBP accumulation is required to maintain quiescence in MEFs, 
I designed experiments to examine cells following Vprbp disruption in conditional MEFs.  
Unfortunately, I could not obtain high density cultures of Vprbp disrupted MEFs by 
seeding plates with high numbers of mutant cells because of low efficiency of plate 
attachment (data not shown).   Further, despite repeated attempts, I was unable to 
isolate Vprbp disrupted MEFs from low-serum conditions (data not shown).  To optimize 
the timing of Vprbp disruption, I treated VprbpF/F and VprbpF/F; CreERT2+ MEFs with 1 
mM 4OHT in 0.1% FBS and examined cells at 3d, 4d and 6d following 4OHT treatment; 
4OHT treatment for 3 days in 10% FBS was included as a positive control (Fig. 3.7).  I 
found that VprbpF/F; CreERT2+ MEFs in 10% FBS-containing medium showed decreased 
VprBP protein levels as expected.  However, conditional MEFs cultured in low-serum 
medium showed high levels of VprBP protein at 3 and 4 days following 4OHT treatment.  
Analysis of cell lysates from MEFs at 6 days after 4OHT showed a minor decrease in 
VprBP protein.  However, very few of the VprbpF/F;CreERT2+ MEF cells remained viable 
6 days after 4OHT treatment.    This observation suggests that VprBP may be required 
for cell survival in low-serum medium, and perhaps more broadly in quiescence because 
only cells which retain VprBP can survive.  Further experiments are needed to test this 
model and specifically to identify a function for VprBP in maintaining quiescence.      
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Figure 3.7 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.  Vprbp disruption is inefficient following serum starvation.   
(A) VprbpF/F or VprbpF/F;CreERT2+ MEFs were treated with 1 mM 4OHT in DMEM with 
10% FBS or with 1 mM 4OHT in DMEM with 0.1% FBS for the number of days indicated.    
VprBP levels remained high despite induction of Cre.   
 
(B)  VprbpF/F or VprbpF/F;CreERT2+ MEFs were treated with 1 mM 4OHT in DMEM with 
0.1% FBS, cultured for 6 days, and then lysed.   
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Discussion 
In this chapter, I examined the function of VprBP in wild-type and conditional 
MEF cells.  I found that Cre-mediated disruption of the conditional allele of Vprbp did not 
result in a complete loss of VprBP, but rather a loss of full-length VprBP and the 
appearance of very low levels of a truncated VprBPD protein.  My characterization of the 
VprbpD allele in MEFs demonstrated that Vprbp disruption was phenotypically similar to 
cultured cells depleted of VprBP by RNAi as assessed by cell proliferation and ability to 
enter S-phase.  I was unable to verify Merlin as putative substrate for ubiquitylation by 
CRL4VprBP, in agreement with a publication by the Giancotti lab (Li et al., 2010b).  
However, experiments designed to test for Merlin degradation following serum 
stimulation unexpectedly uncovered abundant accumulation of VprBP protein in contact 
inhibited and serum starved wild-type MEFs.  This accumulation was particularly 
pronounced in MEFs, but was observed to a lesser extent in WI38 or MCF10A cells, 
suggesting this function of VprBP is possibly cell-type dependent.  Further, disruption of 
Vprbp in conditional MEFs was incompatible with survival in low-serum conditions, 
suggesting that VprBP may be required for quiescent MEFs or for tolerance of restrictive 
growth conditions.     
The results presented in this chapter provide a more complicated view of the 
function of Vprbp in cells than previously appreciated.  I confirmed the essential role for 
Vprbp in cellular proliferation and now provide circumstantial evidence that Vprbp may 
also have a role in non-proliferative, quiescent cells.    The observation that VprBP is 
increased in serum-starved and contact-inhibited cells is particularly intriguing in light of 
its interaction with Merlin.  Some of the earliest research on Merlin showed that Merlin 
accumulates in response to contact inhibition and serum starvation in fibroblasts (Shaw 
et al., 1998).  In contrast to VprBP, Merlin depletion causes loss of contact inhibition 
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(Lallemand et al., 2003; Morrison et al., 2001) which correlates with hyperactive RAC 
and MAPK signaling activity (Kaempchen et al., 2003; Morrison et al., 2007; Okada et 
al., 2005).  The Giancotti lab recently demonstrated that RNAi to VprBP ablates the 
oncogenic activity associated with Merlin loss (Li et al., 2010b).   This suggests that 
VprBP functions downstream of Merlin, perhaps in controlling mitogenic signaling.  While 
the Giancotti lab provide evidence that Merlin and VprBP function in the nucleus to 
control an unknown transcription factor, I favor the long-held view that Merlin functions at 
or near the plasma membrane to inhibit mitogenic signaling (Li et al., 2010b; McClatchey 
and Fehon, 2009).  Indeed, a recent paper finally provided a molecular mechanism for 
the long observed inhibition of RAC signaling by Merlin: Merlin binding to a tight-junction 
associated protein complex releases an inhibitor of RAC called RICH1 (Yi et al., 2011).  
RICH1, also known as ARHGAP17, is a GAP protein that stimulates the conversion of 
RAC-GTP to RAC-GDP, thereby inactivating it.  The Kissil lab now suggest a model that 
RICH1 associates with the tight junction associated protein complex, but is displaced by 
binding of Merlin to the complex, and RICH1 is thought be activated upon its release (Yi 
et al., 2011).     
In our lab, Dr. Tadashi Nakagawa has observed in conditional Vprbp MEFs and 
in RNAi depleted cells that depletion of VprBP results in an almost complete loss of 
GTP-bound RAC from cells (data not shown).  Further, he found that co-depletion of 
Merlin by RNAi rescued this loss of RAC signaling (data not shown).  This suggests that 
VprBP and Merlin may counterbalance each other to fine-tune RAC activity in cells.  It 
will be interesting to determine if VprBP can bind with the tight junction associated 
protein complex (consisting of Angiomotin, PATJ, and PALS1) or RICH1, which would 
provide a direct role for VprBP in regulating RAC activity.  In addition, it will be important 
to determine if loss of RAC signaling underlies the proliferation defect noted in cells 
without VprBP.  Finally, it remains to be seen why VprBP accumulates to such a large 
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extent in quiescent MEFs.  Do high levels of VprBP prime cells to re-enter the cell cycle 
or promote survival during quiescence?  Is binding with Merlin required for VprBP 
function in quiescent cells?  Does VprBP accumulation in contact-inhibited cells relate to 
RAC signaling?  The lab will continue to explore the function of VprBP in proliferative 
and quiescent cells to understand the molecular mechanisms that underlie the 
requirement for VprBP.   
  
     
CHAPTER IV 
 
INDUCIBLE DISRUPTION OF VPRBP IN MOUSE IMPAIRS T-CELL DEVELOPMENT, 
PROLIFERATION AND SURVIVAL 
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Summary 
Vprbp is an essential gene that encodes a putative substrate recruiting receptor for a 
CRL4-RING ubiquitin ligase complex.  To investigate the role of Vprbp in an unbiased 
manner, we disrupted Vprbp in 5-week old mice using a ubiquitously expressed, 4-OH-
tamoxifen-inducible Cre.  We found that disruption of Vprbp results in severe thymic 
defects including a 90.4% reduction in total thymocytes, ablation of CD4+CD8+ cells, 
decreased 5’-bromo-2’-deoxyuridine incorporation and increased cleaved caspase-3 
staining.  We further observed defects in B-cell development with decreased immature 
and pre/pro- B-cell populations.  In addition, we found that mature T-cells from Vprbp 
disrupted mice failed to proliferate in response to CD3/CD28 stimulation, suggesting that 
cell cycle defects underlie the observed phenotypes.  Finally, we found that inducible 
loss of Ddb1 results in a phenotype which considerably overlaps with Vprbp disruption, 
including a reduction in thymus size, decreased CD4+CD8+ population, and impaired B-
cell development. Cumulatively, these data provide the first genetic evidence that Vprbp 
is required beyond embryonic development and demonstrate a specific role for Vprbp in 
lymphocyte development and T-cell proliferation.  Further, observations that Ddb1 or 
Vprbp disruption cause similar defects in lymphocyte development provide genetic 
support for the established biochemical interaction between DDB1 and VprBP.   
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Background 
Ubiquitylation, a post-translational modification best-known for mediating 
proteasomal degradation, is critically involved in regulating a wide range of diverse 
cellular processes.  The largest family of E3s is the cullin-based ubiquitin ligase 
complexes which target numerous substrates by associating with different substrate 
recruiting receptors.    Cullin 4-RING E3 ligases (CRL4s), which use CUL4A or its 
paralog CUL4B as a scaffold, bind linker protein DDB1 (damaged DNA binding) and a 
family of substrate receptors containing a specialized WD40 repeat (Jackson and Xiong, 
2009a).  Here, we describe genetic characterization of mouse Vprbp which encodes a 
putative CRL4 substrate receptor of unknown function. 
VprBP was first identified as the HIV1 viral protein r binding protein, and was 
subsequently shown to associate with CRL4 (Zhang et al., 2001; Zhao et al., 1994; He et 
al., 2006).  Vpr can associate with CRL4VprBP (Belzile et al., 2007; Hrecka et al., 2007; Le 
Rouzic et al., 2007; Tan et al., 2007; Wen et al., 2007) and may hijack the complex to 
degrade UNG2 (Ahn et al. 2010), a uracil DNA glycosylase that removes uracil from 
DNA as part of the base excision repair pathway.  It is unclear if Vpr directs 
ubiquitylation of additional substrates or if Vpr might also function to modulate normal 
CRL4VprBP activity.  CRL4VprBP cannot ubiquitylate UNG2 in the absence of Vpr and its 
normal physiological substrate(s) are unknown.  
The function of VprBP as a substrate recruiting receptor for CRL4 is inferred from 
binding with the CUL4-DDB1-ROC1 complex and the presence of the WDXR motif that 
is shared in other experimentally demonstrated CRL4 substrate receptors.  Without any 
known substrate, the in vivo function of CRL4VprBP remains obscure, but a possible 
function in DNA replication has been proposed.  Knocking down VprBP resulted in 
defective progression through S phase and inhibited proliferation (McCall et al., 2008), 
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(Hrecka et al., 2007), indicating that VprBP is required for normal cell cycle progression 
in cultured cells. 
Genetic studies in several model organisms have established a role for Vprbp in 
embryonic development.  Loss of VPRBP in Arabidopsis led to early embryonic lethality 
at the globular stage, and reduced expression of VPRBP disrupted multiple 
developmental pathways, indicating broad functions in development (Zhang et al., 2008).  
In Drosophila, vprbp/mahjong is required for embryogenesis, but zygotic mutants (which 
have maternally supplied Vprbp) develop normally, suggesting that unlike plants, vprbp 
is only essential for early embryogenesis in Drosophila (Tamori et al. 2010).  We 
previously generated a strain of Vprbp knockout mouse, and found that loss of Vprbp 
causes early embryonic lethality (prior to E7.5) whereas conditional ablation of Vprbp in 
mouse embryonic fibroblasts (MEFs) resulted in cell cycle arrest and apoptosis (McCall 
et al., 2008). Collectively, these studies demonstrate an evolutionarily conserved, 
essential role for Vprbp in early embryonic development.  In this study, we sought to 
genetically examine the in vivo function of Vprbp in adult mice by using a broadly 
expressed, tamoxifen-inducible Cre to drive Vprbp disruption.  This unbiased approach 
uncovered a novel role for Vprbp in the development and proliferation of lymphocytes in 
mice.   
Cell proliferation and apoptosis are both critical for proper lymphocyte 
development.  Developing B- and T-cells have several selection points to ensure that 
gene rearrangement has yielded a productive receptor that responds to specific antigens 
but is not self-reactive.  In the case of thymocytes, CD4-CD8- cells undergo  selection 
following T-cell receptor  (TCR ) gene rearrangement, which dimerizes with the 
proTCR  to express the pro-TCR.  Cells which can relay intra-cellular TCR signals 
survive, undergo a rapid proliferative burst (Vasseur et al., 2001) and further 
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differentiate, while those that fail undergo apoptosis (Zhang et al., 2005).  The TCR  
gene locus is rearranged at the CD4+CD8+ stage and cells are subjected to both 
positive selection (selection for T cells with TCR  binding to self MHC molecules) and 
negative selection (selection against self-reactive cells) before committing to CD4+ or 
CD8+ lineages (Starr et al., 2003).  Many double-positive cells fail to successfully signal 
through TCR  at this stage and consequently undergo apoptosis within a few days 
(Carpenter and Bosselut, 2010 ; Starr et al., 2003).  Thus, thymocytes are poised to die 
by apoptosis at several developmental stages and rely on proliferation at distinct stages 
of the differentiation process.   
Loss of function of many essential genes required for proliferation (e.g. Rac1/2, 
Csn5 (Dumont et al., 2009; Guo et al., 2008; Panattoni et al., 2008)), survival (e.g. cFlip, 
Bcl2 (Chau et al., 2005; Veis et al., 1993)) or cellular metabolism (e.g. Pdk1, Lkb1 
(Hinton et al., 2004; Tamas et al., 2010)) results in severe phenotypes in lymphocyte 
development .  For example, loss of cyclin D3 (Ccnd3), which drives the G1 to S-phase 
cell cycle transition in lymphocytes, blocked B-cell development by inhibiting proliferation 
of pre-B-cells (Cooper et al., 2006).  In addition, T-cell development was inhibited; loss 
of cyclin D3 led to reduced thymus size with a decrease in the number of double positive 
and single positive thymocytes (Sicinska et al., 2003).   
The Ubiquitin C promoter-driven CreERT2+ I chose for my study was previously 
used to characterize inducible deletion of the essential gene Atr in adult mice 
(Ruzankina et al., 2007). The Brown lab found that loss of Atr in adult mice led to  
pronounced phenotypes in a number of proliferative tissues including thymus, bone 
marrow, intestine and skin (Ruzankina et al., 2007).   Given the established requirement 
for Vprbp in normal cell cycle progression and survival, we hypothesized that disruption 
of Vprbp would broadly cause defects in proliferating tissues.   I report here that 
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inducible disruption of Vprbp causes defects in B- and T-cell development and 
decreased the survival and cell proliferation of lymphocytes.   
 
Experimental Procedures 
Mice  
Mice were bred and maintained strictly in the University of North Carolina Animal Care 
Facility under protocol approved by the Institutional Animal Care and Use Committee. All 
efforts were made to minimize animal suffering.  The generation of conditional Vprbp 
mice was previously described (McCall et al., 2008).  Conditional Ddb1 mice were 
previously described (Cang et al., 2006). All mice were backcrossed to C57BL/6 for at 
least 4 generations.  Germline transmission of Vprbp and Ddb1- was obtained by 
crossing conditional mice with EIIA-Cre+ mice (Jackson Laboratories, stock 003724).  
Ubc-CreERT2+ mice were previously described and kindly provided by Dr. Eric Brown 
(Ruzankina et al., 2007).  All experiments were performed using gender-matched, 
littermate controls.  5-week-old mice were injected intraperitoneally (i.p.) once per day 
for five consecutive days with 0.4 mol/g body weight tamoxifen (Sigma, T5648) 
prepared in solution as described (Feil et al., 2009).  For BrdU incorporation experiment, 
50 g BrdU (Sigma, B5002) in PBS per g body weight was i.p. injected 4 hours prior to 
sacrifice.  
 
Genotyping 
Primers for genotyping  Vprbp alleles: 5’ CTGGGTAGCTACTGTTGACTACTCACTGCG 
3’, 5’ CAGTTAGAGAGTGACTTTGGACG 3’, and 5’ GCTGCCAACTATGGGTGC 3’, 
which detected 434 bp, 468 bp and 280bp bands for the wild-type, flox and  alleles, 
respectively.    Primers for genotyping conditional Ddb1: 
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5’CGGGACTGGAGCATTTTTGACTAC 3’ and 5’ ATTTTCTGTGTATGGAGGGGAGTG 
3’.  Primers for genotyping conditional Ddb1-: 5’ CCCACTTAAAGGACTGGTG 3’ and 5’ 
GGACAATGGAAACATAGGG 3’.  Primers for genotyping Cre-ERT2: 5’ 
GCTGGAGTTTCAATACCGGAG 3’ and 5’ CTTAGAGCGTTTGATCATGAGC 3’.  Il2 
primers were included in the CreERT2 PCR as an internal control: 5’ 
CTAGGCCACAGAATTGAAAGATCT 3’ and 5’GTAGGTGGAAATTCT AGCATCATC 3’. 
 
Immunohistochemistry and Immunoblotting 
Mouse tissue was removed, fixed in 10% neutral buffered formalin, embedded in paraffin 
and cut into 3- m sections.  Primary antibodies for immunohistochemistry included p53 
(1:500, Novocastra NCL-p53-505), BrdU (1:100, Amersham Pharmacia Biotech BU-1), 
and cleaved caspase-3 (1:400, Cell Signaling 9661) and were detected by 
diaminobenzidine (DAB) staining (Vector Laboratories, Vectastain Elite ABC reagent) 
after unmasking by heating in 10 mM sodium citrate buffer (pH 6.0). 
 
For immunoblotting, tissue or cells were lysed in RIPA buffer (50 mM Tris-HCl [pH 8.0], 
150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 1 mM Na3VO4, supplemented with 1 
mM DTT, 1 mM PMSF, and a cocktail of protease inhibitors containing 25 mg/L 
leupeptin, 25 mg/L aprotinin, 150 mg/L benzamidine, and 10 mg/L trypsin inhibitor), 
resolved by SDS-PAGE and transferred to 0.2 m PVDF (Millipore).  Antibodies to 
VprBP and DDB1 were previously described (McCall et al., 2008).  Antibodies for 
immunoblotting included Actin (Santa Cruz, sc-1616), -tubulin (NeoMarkers, Ab-2), 
PARP (Cell Signaling, 9542) pRB (Cell Signaling, 9308), and RB (BD Pharmingen, G3-
245). 
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Flow Cytometry 
All cells were analyzed at the University of North Carolina School of Medicine Flow 
Cytometry Facility on a CyAN (Dako Cytomation) flow cytometer, and data were 
analyzed using Summit software, version 4.3 (Dako Cytomation).  To examine BrdU 
incorporation in MEFs, cells were prepared as previously described (McCall et al., 2008).  
For thymocyte, splenocyte, and bone marrow cells, single cell suspensions were 
prepared in PBS containing 2% FBS (FACS buffer) after red blood cells lysis in 4 parts 
0.8% NH4Cl, 0.1 mM EDTA, pH 7.45 and 1 part FACS buffer. 10
6 live cells were stained 
in FACS buffer containing Fc block (BioLegend, Trustain fcX, 1:200) with the antibodies 
indicated: Pacific Blue-conjugated CD8a (BioLegend, 1:400), APC-AF750-conjugated 
CD4 (Caltag,1:50), PE-conjugated B220 (BD Biosciences, 1:100), or FITC-conjugated 
IgM (eBioscience, 1:100), and immediately analyzed by flow cytometry. 
 
For in vitro T-cell proliferation experiments, primary lymphocytes were labeled with 5 μM 
carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular Probes, Inc) in PBS at 
room temperature for 10 min; labeling was quenched with the addition of an equal 
volume of FBS followed by two washes in RPMI-10.  T-cells were then stimulated by 
CD3 and CD28 antibodies (Caltag) and cultured in RPMI-10 for the indicated time.  106 
cells were then labeled with Pacific Blue-conjugated CD4 (Biolegend, 1:100) and Pacific 
Blue-conjugated CD8a (Biolegend, 1:400), and subsequently stained with APC-
conjugated Annexin V (eBioscience, 1:20) and 7AAD before flow cytometry analysis.  
 
Cell Culture  
Primary mouse embryo fibroblasts (MEF) were isolated on embryonic day 13.5 and 
grown in a 37°C incubator with 5% CO2 in DMEM supplied with 10% FBS and penicillin-
streptomycin.  All experiments were performed at passage 4 or earlier.  For BrdU 
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incorporation, a final concentration of 10 M BrdU was added to the culture medium for 
6 hours before harvesting and fixing cells.   4-OH-Tamoxifen (Sigma, H7904) was 
dissolved in 100% ethanol and added to the culture medium as indicated.   
 
Primary lymphocytes from mouse lymph nodes and spleen were obtained from 6-week-
old tam-treated mice 6 days following the first injection.  After red blood cell lysis, cells 
were cultured in RMPI (Gibco) supplemented with 10% FBS, penicillin-streptomycin, 2 
mm L-glutamine, 50 M -mercaptoethanol, and 100nM 4-OHT.  Cells were cultured for 
18h before CFSE labeling and T-cell activation. 
 
qPCR 
Total RNA was extracted by RNeasy (Qiagen), and used for cDNA synthesis primed with 
Oligo(dT)20 primers (Invitrogen, Superscript III). The cDNA was added to a qPCR 
mixture that contained 1× SYBR Green PCR master mix (Applied Biosystems) and 500 
nM gene-specific primers. Assays were performed in triplicate on a 7900 HT sequence 
detection system (Applied Biosystems). The PCR protocol comprised incubations for 2 
min at 50°C and for 10 min 95°C, followed by 40 cycles, each consisting of 15 sec at 
95°C and 1 min at 60°C. The expression level of each gene was normalized with 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh).  The specific PCR pairs were as 
follows: Vprbp: 5’ GCCGGGCCTAGAAACCGCAG 3’, 5’ 
TGTCCTGCCGCAAAGCCACT; Ddb1: 5’ GCAGAGCCCAAGCAGGGTCG 3’, 
5’GCCGCACCGTGCTATTGATGC ; Gapdh: 5’ AGCCTCGTCCCGTAGACAA 3’, 5’ 
AATCTCCACTTTGCCACTGC 3’.  For qPCR of genomic DNA from paraffin-embedded 
tissue, the following primers for Vprbp were used:  5’ 
TGCAGGTCACTCCTGATTAAGGGT 3’ (in intron 7-8) and 5’ 
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GAGTGCCTCAAAAGTAAGCAGGACA 3’ (in exon 8).  Detection of Vprbp was 
normalized to Il2, which was unaffected by Cre recombination: 5’ 
CTAGGCCACAGAATTGAAAGATCT 3’ and 5’GTAGGTGGAAATTCT AGCATCATC 3’. 
 
Results 
Inducible disruption of Vprbp results in marked thymic atrophy 
To genetically examine the in vivo function of Vprbp in mice, we administered 
tamoxifen (tam) to VprbpF/ ;CreERT2+   and littermate control VprbpF/+;CreERT2+ mice 
and observed loss of full-length VprBP in multiple tissues including heart, liver, kidney 
and brain (Fig. 4.1A).  We found that 43.8% (14/32) of mutant mice became moribund 
within 7 to 14 days after initial tam injection, indicating that disruption of Vprbp is poorly 
tolerated in adult mice.   Further, the appearance of this severe phenotype correlated 
closely with the efficiency of Vprbp disruption as assessed by immunoblotting or qRT-
PCR, suggesting that the variation between animals reflects varying degrees of Cre-
mediated recombination in mice (data not shown).  In the course of analyzing these 
mice, we noted obvious thymic atrophy in tam-treated VprbpF/ ;CreERT2+ mice (Fig. 
4.1B) and have therefore chosen to focus our efforts on characterizing in detail the 
effects of Vprbp disruption in thymus.  In addition to reduced size, histological analysis of 
thymus from a VprbpF/ ;CreERT2+ mouse after tam treatment revealed a clear lack of 
typical cortico-medullary architecture (Fig. 4.1C), suggesting T-cell developmental 
defects.  
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Figure 4.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Inducible disruption of Vprbp results in marked thymic atrophy  
 
(A) Tamoxifen administration resulted in loss of VprBP protein in a broad range of 
tissues.  Tissue lysates from tamoxifen-treated VprbpF/+;CreERT2+ or VprbpF/ ;CreERT2+ 
mice were prepared, resolved by SDS-PAGE and immunoblotted as indicated.   
 
(B) Disruption of Vprbp resulted in a visibly smaller thymus. Thymi were isolated from 6-
week-old VprbpF/+;CreERT2+ or VprbpF/ ;CreERT2+ mice, 7 d after tamoxifen injection.   
 
(C) Disruption of Vprbp caused disorganized thymic structure.  Sections of formalin-
fixed, paraffin-embedded thymus tissue were stained with hematoxylin and eosin.  
Cortex (Cx) and medulla (M) are indicated in thymus from tamoxifen-treated 
VprbpF/+;CreERT2+, but are not well-defined in thymus tissue from a VprbpF/ ;CreERT2+ 
mouse.  Scale bar = 200 m.
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Defects in T-lymphocyte development following inducible disruption of Vprbp 
Total thymocyte cell counts were significantly reduced in thymus from tam-
treated VprbpF/ ;CreERT2+ mice (1.36 ± 0.67 × 107 in mutant vs. 15.52 ± 1.37 × 107 in 
control animals 7-10 days after tam treatment, p=0.0005; Fig. 4.2A), indicating a severe 
T-cell developmental defect. To further probe the nature of the T-cell developmental 
defect, flow cytometric analysis of CD4 and CD8 cell surface markers was performed on 
thymocytes from tam-treated VprbpF/ ;CreERT2+ mice compared with tam-treated 
VprbpF/+;CreERT2+ control mice. T-cell precursors migrate to the thymus as double 
negative (CD4− CD8−, DN), mature into double positive (CD4+ CD8+, DP) cells, and 
subsequently commit to become single positive (CD4+ or CD8+) cells.   In the mutant 
thymus, CD4/CD8 staining notably revealed a near complete loss of the DP cells, with a 
corresponding relative increase in the percentage of DN and SP cells (Fig. 4.2B-C).   
While this result could suggest a block in the DN to DP transition (with residual SP cells 
developed before tam-treatment), the absolute number of DN and SP cells was also 
greatly reduced (Fig. 4.2D), indicating decreased survival at all developmental stages, 
with DP cells being the most profoundly affected. RT-PCR analysis of thymic tissue 
indicated that the majority of remaining cells retained full length Vprbp mRNA (Fig. 
4.2E), indicative of a strong selection pressure against cells with Cre-mediated 
recombination in thymus despite good recombination in other tissues in the same mice 
(Fig. 4.2E and data not shown).   
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Figure 4.2 
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Figure 4.2. Defects in T-lymphocyte development following disruption of Vprbp 
 
(A) Total thymic cellularity (x106) in 6-wk-old VprbpF/+;CreERT2+ and VprbpF/ ;CreERT2+ 
mice 6-10 days after tamoxifen treatment.  Single cell suspensions prepared from 
thymus were quantified using a hemacytometer (n=6 for VprbpF/+;CreERT2+ and n=6 for 
VprbpF/ ;CreERT2+ mice).     
 
(B) Flow cytometric analysis of thymocytes from VprbpF/+;CreERT2+ and 
VprbpF/ ;CreERT2+ mice 6 d after tamoxifen injection, stained with Pacific Blue-
conjugated CD8 antibody and APC-AF750-conjugated CD4 antibody.   
 
(C) Bar diagram showing average percentages for CD4- CD8- (DN), CD4+ CD8+ (DP), 
CD4+ SP and CD8+ SP subpopulations from 6-wk-old mice 7 d after initial tamoxifen 
treatment (n=3 for VprbpF/+;CreERT2+ and n=3 for VprbpF/ ;CreERT2+ mice).  Values 
represent the mean ± SE.     
 
(D) Absolute cell numbers (x106) for thymocyte subsets in C were calculated by 
multiplying percentages by total cell number.  Values represent the mean ± SE.    
 
(E) Thymus tissue remaining in VprbpF/ ;CreERT2+ mice following tamoxifen treatment 
has largely escaped Cre-mediated recombination.  The mRNA level of full length Vprbp 
transcript from kidney and thymus tissue from the same mice was determined by 
quantitative real-time reverse transcriptase PCR (qRT-PCR). Data are expressed 
relative to the corresponding values for VprbpF/+;CreERT2+ thymus or kidney.  Each 
experiment was performed in triplicate; mean value and standard deviations were 
calculated from three independent experiments.
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Disruption of Vprbp decreased proliferation and induced apoptosis in thymus.   
 To examine how Vprbp disruption effects cell survival and cell proliferation, we 
examined the histology of thymus sections from more moderately affected animals (6 d 
after tam), at which time there was robust recombination at the Vprbp loci as assessed 
by qPCR analysis of genomic DNA from thymic tissue (data not shown).  Incorporation 
of the thymidine analog BrdU was almost undetectable in thymus from mutant mice, 
indicating a strong inhibition of proliferation (Fig. 4.3A).  In addition, cleaved caspase-3 
and p53 are more abundantly detected following Vprbp disruption, indicating that, in 
addition to proliferation inhibition, apoptosis also contributes to the reduction in thymus 
size in mutant mice (Fig. 4.3A).  Consistent with these observations, western blot 
analysis revealed an increase in p53 protein and reduced proliferation, as assessed by 
lack of phosphorylated-RB protein, in thymocytes from tam-treated VprbpF/ ;CreERT2+ 
mice compared to control animals (Fig. 4.3B).  Furthermore, we noted an increase in 
apoptotic and dead cells in the mutant DP population compared with control DP cells, as 
assessed by Annexin V+ and 7AAD staining (Fig. 4.3C), indicating that disruption of 
Vprbp promotes apoptosis of DP thymocytes.  
 
Inducible disruption of Vprbp disrupts B-cell development.   
Having observed a clear requirement for Vprbp in T-cell development, we sought 
to determine if Vprbp also played a role in B-cell development by examining the effect of 
Vprbp disruption on bone marrow.  We assessed the efficiency of Vprbp disruption by 
qRT-PCR analysis of isolated bone marrow cells (Fig. 4.4B).  We found that the total 
number of bone marrow cells from femurs was reduced (7.76 ± 1.60 × 106 in mutant 
versus 13.94 ± 1.41 × 106 in control animals 6-10 days after tam treatment; Fig. 4.4C), 
though this difference was not statistically significant.  Histological analysis of bone  
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Figure 4.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Vprbp disruption decreased proliferation and induced apoptosis in 
thymus 
 
(A) Immunostaining of BrdU, cleaved caspase-3 and p53 from sections of formalin-fixed, 
paraffin-embedded thymus tissue following tamoxifen treatment.  Positive staining is 
indicated by brown color; sections were counter-stained with hematoxylin.  Scale bar = 
20 m.   
 
(B) Immunoblot analysis, using the indicated antibodies, of thymocyte lysate from 
VprbpF/+;CreERT2+ and VprbpF/ ;CreERT2+ mice 6d after initial tamoxifen treatment  
 
(C) Flow cytometric analysis of apoptotic cells by 7AAD and Annexin V staining, gated 
by the CD4+CD8+ population.     
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Figure 4.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.  Inducible disruption of Vprbp impairs B-cell development  
(A) Bone marrow cells from one femur of VprbpF/+;CreERT2+ and VprbpF/ ;CreERT2+ 
mice were isolated 6 d after tamoxifen injection, stained with PE-conjugated B220 
antibody and FITC-conjugated IgM antibody, and analyzed on a flow cytometer.   
 
(B)  Vprbp mRNA levels from bone marrow were determined by quantitative real-time 
reverse transcriptase PCR (qRT-PCR). Data are expressed relative to the corresponding 
values for VprbpF/+;CreERT2+.  Each experiment was performed in triplicate; mean value 
and standard deviations were calculated from three independent experiments.   
 
(C)  Total bone marrow cellularity (x106) in 6-wk-old VprbpF/+;CreERT2+ and 
VprbpF/ ;CreERT2+ mice 6 days after tamoxifen treatment.  Single cell suspensions were 
quantified using a hemacytometer (n=4 for VprbpF/+;CreERT2+ and n=4 for 
VprbpF/ ;CreERT2+ mice).   
 
(D)  Sections of decalcified, paraffin-embedded bone marrow tissue were stained with 
hematoxylin and eosin.  Scale bar = 20 m. 
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marrow tissue supported the notion that bone marrow cellularity decreased following tam 
injection in VprbpF/ ;CreERT2+ mice (Fig. 4.4D). To examine how Vprbp disruption 
specifically affects B-cell development, we analyzed the B-cell subpopulations of isolated 
bone marrow cells from femurs by staining the cell surface for B-cell markers B220 and 
IgM.  We found that the B220+IgM─ cells, which represents pre- and pro-B-cell 
populations, were reduced in tam-treated VprbpF ;CreERT2+ mice (8.3% in mutant 
versus 25.1% in control) as were the B220loIgM+ cells, which represents immature B-
cells (3.8% in mutant versus 6.8% in control; Fig. 4.4A).   Concomitantly, a relative 
increase in the percentage of recirculating, mature B-cells which are B220hiIgM+ was 
found in bone marrow of in tam-treated VprbpF/ ;CreERT2+ mice  (38.6% in mutant 
versus 18.1% in control bone marrow; Fig. 4.4A).  This finding suggests that B-cells 
which matured prior to tam injection in VprbpF/ ;CreERT2+ mice were largely unaffected 
by Vprbp disruption, but new B-cell development in bone marrow was inhibited.   Thus, 
we conclude that disruption of Vprbp impairs the development of both B- and T-cells in 
mice. 
 
Mature T-cells with disrupted Vprbp fail to proliferate in response to activation. 
To examine the effects of Vprbp disruption on mature, rather than developing 
lymphocytes, we examined B- and T- cell populations from spleen tissue.  We found a 
decrease in spleen size (Fig. 4.5A) and splenocyte cellularity following inducible 
disruption of Vprbp (8.18 ± 0.89 × 107 in mutant vs. 13.52 ± 0.98 × 107 in control animals 
6-10 days after tam treatment, p=0.014; Fig. 4.5B).  However, flow cytometric analysis of 
the B- and T-cell populations from spleen showed no change in the relative percentage 
of lymphocytes following Vprbp disruption.  This observation suggests that developing B-  
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Figure 4.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5.  Disruption of Vprbp did not impact the distribution of splenocytes.   
 
(A)  Gross morphology of spleen 6 d after tamoxifen treatment in 6-wk-old 
VprbpF/+;CreERT2+ and VprbpF/ ;CreERT2+ mice.   
 
(B) Total splenocyte cellularity (x107) in 6-wk-old VprbpF/+;CreERT2+ and 
VprbpF/ ;CreERT2+ mice 6-10 days after tamoxifen treatment.  Single cell suspensions 
were quantified following red blood cell lysis using a hemacytometer (n=5 for 
VprbpF/+;CreERT2+ and n=5 for VprbpF/ ;CreERT2+ mice).   
 
(C) Vprbp mRNA levels from spleen tissue were determined by quantitative real-time 
reverse transcriptase PCR (qRT-PCR). Data are expressed relative to the corresponding 
values for VprbpF/+;CreERT2+.  Each experiment was performed in triplicate; mean value 
and standard deviations were calculated from three independent experiments.    
 
(D) Flow cytometric analysis of the B-cell population in spleen was determined by 
staining splenocytes with PE-conjugated B220 antibody and FITC-conjugated IgM 
antibody.  Flow cytometric analysis of the T-cell population in spleen was determined by 
staining splenocytes with stained with Pacific Blue-conjugated CD8 antibody and APC-
AF750-conjugated CD4 antibody.  
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and T-cells are more severely affected by Vprbp disruption than mature lymphocytes, 
possibly reflecting the G0 state of naïve, mature T- and B-cells.    
We hypothesized that the developmental defect present in T-cells was likely due 
to a failure of thymocytes to proliferate, rather than a requirement for Vprbp in pathways 
specific to T-cell development (e.g. V(D)J recombination or positive or negative 
selection).  To test for a requirement of Vprbp in cell proliferation independent of its role 
in T-cell development, we stimulated mature T-cell proliferation in vitro and subsequently 
monitored cell divisions.  We isolated mature lymphocytes from tam-treated 
VprbpF/ ;CreERT2+ mice and control Vprbp ;CreERT2+ and confirmed a decrease in 
VprBP by immunoblotting (Fig. 4.6A).  In addition, we saw no evidence for PARP 
cleavage, indicative of apoptosis, in mutant lymphocytes suggesting disruption of Vprbp 
did not affect the survival of resting lymphocytes (Fig. 4.6A).  In addition, we saw no 
evidence for apoptosis in mutant lymphocytes, suggesting disruption of Vprbp did not 
affect the survival of resting lymphocytes (Fig. 4.6A).  To follow cell divisions, 
lymphocytes were labeled with CFSE (carboxyfluorescein succinimidyl ester), a 
fluorescent dye that forms stable adducts on intracellular proteins and provide a 
quantitative measurement of cell division by using flow cytometry as it is diluted by half 
following each cell division. T-cell proliferation was activated by anti-CD3 in the presence 
of anti-CD28 co-stimulation followed by in vitro culture.  We collected cells at 42h, 54h, 
and 66h after stimulation or mock treatment and monitored the proliferation of T-cells by 
flow cytometry.  We found that whereas control cells showed continued, robust 
proliferation in response to activation, very few mutant T-cells proliferated in response to 
activation 42h and 54h and less than half had undergone any proliferation at 66h (Fig. 
4.6C).  These data indicate that Vprbp is required for normal T-cell proliferation in 
response to CD3/CD28 stimulation. In agreement with this observation, the total cell 
number following T-cell stimulation was decreased in Vprbp disrupted primary 
 93 
 
Figure 4.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.  Vprbp disruption impairs mature T-cell proliferation 
 
(A) Immunoblotting of cell lysates from primary lymphocytes derived from tam-treated 
VprbpF/+;CreERT2+ and VprbpF/ ;CreERT2+ mice 6 days after initial tam-treatment.   
 
(B) T-cells in primary lymphocyte cultures from tam-treated VprbpF/+;CreERT2+ and 
VprbpF/ ;CreERT2+ mice were stimulated with CD3/CD28 or mock treated and plated at 
equal cell numbers.  The total cell number following activation, expressed relative to the 
number of mock treated cells, is reported at 2 and 3 days after CD3/28 stimulation.   
 
(C) Primary lymphocytes labeled with CFSE, followed by CD3/CD28 stimulation or 
mock.  Cells were cultured in vitro for 42h, 54h, or 66h before collection.  Flow 
cytometric analysis for CFSE was used to determine the proliferation, gated by 7AAD- T-
cells.   
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 lymphocytes versus control primary lymphocytes following T-cell activation (Fig. 4.6B).  
Therefore, we conclude that Vprbp is required for the proliferation of mature T-cells and 
suggest that decreased proliferative capacity may account for the developmental defects 
observed in B- and T-cells. 
 
Loss of Ddb1 disrupts B- and T-cell development.   
VprBP is thought to function as part of a CRL4 ligase through binding to the 
linker protein DDB1.  We therefore predicted that loss of Ddb1 should phenocopy Vprbp 
disruption.   To test this notion, we induced conditional loss of Ddb1 using Ubc-Cre-
ERT2 to drive Cre expression in 5-week-old mice and confirmed broad loss of DDB1 in a 
variety of tissues by immunoblotting (Fig. 4.7A).  We found that inducible loss of Ddb1 
typically caused death 5 to 8 days after initial tam injection (data not shown).  In addition, 
we observed a pronounced reduction in thymus size, suggesting that loss of Ddb1 also 
impacts T-cell development (Fig. 4.7B).  We further examined T-cell development 
following inducible loss of Ddb1 by CD4/8 staining of thymocytes and found a marked 
decrease of DP cells (17.9% in mutant thymus versus 71.3% in control) with a 
concurrent increase in CD4+ and CD8+ cells (Fig. 4.7C), similar to observations in Vprbp 
disrupted thymus.  Disruption of Ddb1 was confirmed by immunoblotting of thymocyte 
cell lysate for DDB1 (Fig. 4.7C).  These results suggest that Ddb1 is required for normal 
T-cell development in vivo.  Likewise, we observed that B-cell development, as 
monitored by B220 and IgM surface staining of femur-derived bone marrow cells, was 
also disrupted following inducible loss of Ddb1, with a decrease in pre-/pro-B-cells 
(14.6% in mutant versus 30.0% in control) and an increase in the population of mature 
B220hiIgM+ cells (39.4% in mutant versus 23.6% in control; Fig. 4.7D).  We interpret 
these results to indicate that new B-cell development is impaired following Ddb1 loss, 
but B-cells which matured prior to tam-treatment survive loss of Ddb1.  This phenotype,  
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Figure 4.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Loss of Ddb1 impairs lymphocyte development. 
(A) Tamoxifen administration resulted in loss of DDB1 protein in a broad range of 
tissues.  Tissue lysates from tamoxifen-treated Ddb1F/+;CreERT2+ or Ddb1F/-;CreERT2+ 
mice were prepared 6 d after tamoxifen injection, resolved by SDS-PAGE and 
immunoblotted as indicated.   
 
(B) Gross morphology of thymus in 6-wk-old Ddb1F/+;CreERT2+ and Ddb1F/-;CreERT2+  
mice 6 d after tamoxifen treatment.   
 
(C) Representative flow cytometric analysis of thymocytes from Ddb1F/+;CreERT2+ and 
Ddb1 ;CreERT2+ mice stained with Pacific Blue-conjugated CD8 antibody and APC-
AF750-conjugated CD4 antibody.   
 
(D) Immunoblot of cellular lysate of thymocytes in (C).   
 
(E) Representative flow cytometric analysis of bone marrow cells from 
Ddb1F/+;CreERT2+ and Ddb1F/-;CreERT2+ mice stained with FITC-conjugated IgM 
antibody and PE-conjugated B220 antibody.  
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which largely overlaps with observations following Vprbp disruption, provides genetic 
support for the biochemically established interaction between VprBP and DDB1.   
 
Discussion 
In this paper, we provide the first genetic evidence that Vprbp is required in adult 
mice.   Using a broadly expressed, tamoxifen-inducible Cre, we showed that disruption 
of Vprbp causes defects in B- and T-cell development and decreased the survival and 
cell proliferation of thymocytes.  Inducible loss of Vprbp significantly decreased 
thymocyte cellularity, nearly completely ablated the CD4+CD8+ population of thymocytes, 
severely disrupted thymic structure, inhibited BrdU incorporation, and increased cleaved 
caspase 3 staining.   Further, we found that Vprbp disruption severely inhibited the 
proliferation of mature T-cells in response to CD3/CD28 stimulation.  We suggest that 
Vprbp is broadly required for cell proliferation, and that developmental defects in T-cells 
reflect a requirement for Vprbp in the cell cycle of developing lymphocytes. Supporting 
this notion, we observed depletion of the absolute number of all stages of thymocytes, 
but did not observe an accumulation of Vprbp  cells at any specific developmental 
timepoint, a finding that would argue against a specific role for Vprbp during thymocyte 
development. Given that cell proliferation and apoptosis are both critical for proper 
lymphocyte development and that significant proliferative defects and apoptosis in 
Vprbp-deficient thymus, we further suggest that VprBP plays a role required for both cell 
cycle progression and survival during T-cell development.   
We also provide the first genetic evidence supporting the biochemical finding that 
VprBP is a component of and may functionally depend on the DDB1-mediated E3 ligase. 
We found that loss of Ddb1 caused similar defects in thymus as VprBP-deficient thymus.  
Ddb1 has previously been established to play an essential role in proliferation, survival, 
and development in multiple tissue types.  Genetic analysis following loss of Ddb1 in 
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developing mouse brain or skin both demonstrated that Ddb1 is essential for proper 
development and that loss of Ddb1 induces p53-dependent apoptosis in proliferating 
cells (Cang et al., 2006; Cang et al., 2007). Further, albumin-Cre driven deletion of Ddb1 
was recently shown to result in obligatory proliferation of DDB1 expressing hepatocytes 
to replace dying Ddb1-deleted cells confirming a function for Ddb1 in cell survival 
(Yamaji et al.).  Our studies of conditional deletion of Ddb1 in thymus reveal a new 
function of Ddb1 in T-cell proliferation and development and support the notion that 
CUL4-DDB1 E3 ligase, via interacting with multiple DWD/DCAF proteins, may target 
ubiquitylation of multiple proteins and play broad functions in vivo.     
   Our studies also provide a new mechanistic insight regarding Vpr-VprBP 
interaction. Although not essential for HIV-1 replication in cell culture, the Vpr accessory 
protein plays an important function for lentivirus pathogenesis as evidenced by its 
conservation in HIV-1, HIV-2 and SIV viruses and by the attenuated progression of AIDS 
in rhesus monkeys infected with SIV missing Vpr and the very similar accessory protein 
Vpx (Gibbs et al., 1995). How Vpr facilitates HIV pathogenesis, however, remains 
unclear. One consistent effect on host cells upon ectopic expression of Vpr has been its 
ability to cause G2 cell cycle arrest (Jowett et al., 1995; Rogel et al., 1995). Our finding 
that the function of VprBP is required for both T-cell proliferation and survival can be 
reconciled with previous findings by a model that Vpr binds to and activates the function 
of VprBP to benefit HIV propagation. Given that a G2 cell cycle arrest can only be 
achieved during active cell proliferation, not in quiescent cells, we speculate that during 
this activation of VprBP’s function to promote cell proliferation, Vpr hijacks CRL4VprBP E3 
ligase to degrade a protein(s) which causes G2 arrest.  
While we have firmly established a role for Vprbp in cellular proliferation in vivo, 
the underlying molecular mechanism remains obscure.  Although the tumor suppressor 
protein Merlin was initially reported as a substrate for the CRL4VprBP complex (Huang and 
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Chen, 2008), it was also proposed to function as an upstream inhibitor of VprBP (Li et 
al., 2010b). At present, neither targeting Merlin for ubiquitylation nor the inhibition of 
VprBP-mediated E3 ligase(s) by Merlin provides a clear molecular model for the function 
of VprBP in T cell proliferation and survival. In addition to Merlin, VprBP and DDB1 were 
identified as components of a novel EDD1 HECT E3 ligase complex that targets Katanin 
p60, the catalytic subunit of the microtubule-severing AAA ATPase katanin complex, for 
ubiquitylation (Maddika and Chen, 2009).  Katanin has previously been established to 
play a role in severing microtubles during mitosis (McNally and Thomas, 1998; McNally 
et al., 2006), and overexpression of katanin p60 is associated with an accumulation of 
4N cells and increased phospho-H3 staining, indicative of mitotic defects (Maddika and 
Chen, 2009).  Unfortunately, we were unable to detect accumulation of endogenous 
katanin p60 following disruption of Vprbp due to lack of specificity of the katanin p60 
antibody for mouse katanin p60 (data not shown).  Inducible disruption of Vprbp in MEFs 
(Fig. 4.1), like reported results following knockdown experiments (Hrecka et al., 2007; 
McCall et al., 2008), resulted in cell cycle arrest, but was not associated specifically with 
a G2/M arrest, suggesting that, at a minimum, katanin p60 is not the sole target of 
VprBP in vivo.  Thus, future efforts will focus on the identification of CRL4VprBP 
substrate(s).  
 
 
     
CHAPTER V 
 
CONCLUSIONS AND PERSPECTIVES 
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Over the course of the last several years, I have extensively focused on the in 
vivo function of VprBP, and uncovered definitive evidence for a role of Vprbp in the 
proliferation and survival of developing of B- and T-cells in mice.  Furthermore, my 
studies in mouse embryonic fibroblasts correlatively suggest that VprBP may also 
function in maintaining quiescent cells and contact inhibition.   Despite numerous studies 
of VprBP from many different perspectives (e.g. HIV1 research, association with tumor 
suppressor Merlin, as well as genetic studies in Arabidopsis, Drosophila and mice), we 
still know surprisingly little about the in vivo functions of VprBP.  Genetic studies 
consistently demonstrate a function in early embryonic development, and human cell 
culture studies consistently indicate a function in cellular proliferation.  In addition, VprBP 
is abundantly expressed throughout the body and is readily detected in CRL4 
complexes.  We infer that the biochemical mechanism of VprBP is through ubiquitylation 
of substrate proteins via a CRL4 complex.  However, the identity and in vivo function of 
such substrates remains completely obscure.  In this final chapter, I provide a 
perspective on the key outstanding questions in the field of VprBP research, and 
conclude by suggesting possible experiments to identify potential substrates and 
genetically address the in vivo function of Vprbp.  
 
Does VprBP have CRL4-independent functions? 
Maddika and Chen identified VprBP and DDB1 as components of a novel E3 
ligase that uses DYRK2 (a member of evolutionarily conserved dual-specificity tyrosine 
(Y)-regulated kinases) as a scaffold for the assembly of a HECT E3 complex, indicating 
that VprBP functions outside of the CRL4 complex (Maddika and Chen, 2009; Jackson 
and Xiong, 2009b). This finding was particularly unexpected given the central role 
established for DDB1 as the key adaptor protein for recruiting substrate to CRL4s (He et 
al., 2006; Higa et al., 2006b; Angers et al., 2006; Jin et al., 2006).  The DYRK2-DDB1-
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VprBP complex also contained EDD (E3 identified by differential display), a large protein 
containing multiple domains linked to ubiquitylation, including an N-terminal ubiquitin 
associated (UBA) domain, a UBR box (a motif important for the targeting of N-end rule 
substrates) and a C-terminal HECT domain.  
Genetic studies in C. elegans previously demonstrated the DYRK2 homolog 
MBK-2 regulates the meiotic protein, MEI-1/katanin, the catalytic subunit of the 
microtubule-severing AAA ATPase complex (Lu and Mains, 2007). This finding 
prompted Maddika and Chen to test whether mammalian katanin p60 was a substrate 
for the DYRK2 E3 complex, referred to as EDVP (EDD–DDB1–VprBP). In vitro binding 
and in vivo ubiquitylation assays demonstrated that katanin p60 associates with and is 
polyubiquitylated by the EDVP E3 ligase complex.  Further, VprBP was required for 
association of katanin p60 with other complex subunits.   Notably, no CUL4A, CUL4B or 
ROC1 was detected in the complex. Silencing individual components of EDVP, but not 
CUL4A and CUL4B, severely impaired katanin polyubiquitylation. 
The authors did not, however, investigate a potential role for the WD40 protein 
katanin p80, the major cellular binding partner for katanin p60 which contains a single 
WDXR motif.  Previous studies of the microtubule severing activity of the katanin 
complex indicated that the WD40 domain of katanin p80 negatively regulates the 
enzymatic activity of katanin p60 (McNally et al., 2000).  It remains possible that 
insufficient knockdown of CUL4A/B masked the role of CUL4 and minimally suggests 
that possible involvement of katanin p80 in a CRL4 complex merits exploration.   In my 
own hands, I have verified that a small percentage of endogenous VprBP can indeed 
associate with DYRK2 in cultured cells (data not shown), consistent with published 
results on the EDVP complex.  However, I was unable to verify accumulation of 
endogenous katanin p60 following loss of Vprbp in MEFs or VprBP knockdown in 
cultured cells due to lack of specificity of the katanin p60 antibody.  In addition, Maddika 
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and Chen showed that ectopic expression of katanin caused an increase in cells with 4N 
DNA content and positive for phopho-histone H3, indicative of mitotic defects (Maddika 
and Chen, 2009).  Depletion of VprBP results in cell cycle arrest, but is not associated 
specifically with a G2/M arrest, suggesting that katanin p60 is minimally not the sole 
target of VprBP in vivo.  I favor a model whereby the primary functions of VprBP are 
mediated by CRL4, based in part on the abundant binding of VprBP to CRL4 and CSN 
components in vivo, and I suggest that involvement in the EDVP complex accounts for a 
minor portion of VprBP function.   
 
VprBP likely targets a diverse set of substrates 
 A single CRL complex can target multiple different substrates for ubiquitylation, 
as has been demonstrated for SCFSKP2, SCF TRCP, SCFFBW7, CRL4DDB2, and CRL4CDT2 
(Frescas and Pagano, 2008; Welcker and Clurman, 2008; Jackson and Xiong, 2009a).  
In the case of CRL4CDT2, substrate polyubiquitylation requires binding to PCNA on 
chromatin and is tightly coupled with DNA replication and/or repair.  For example, proper 
CRL4CDT2-mediated destruction of CDT1, p21,  Drosophila E2f1,  and SET8 during S-
phase is required for proper cell cycle progression, while UV-induced DNA damage 
triggers ubiquitylation of  CDT1 and p21, to restrict DNA licensing, as well as polymerase 
η and PCNA to facilitate proper translesion synthesis (Arias and Walter, 2006; Hu and 
Xiong, 2006; Senga et al., 2006; Abbas et al., 2008; Kim et al., 2008; Nishitani et al., 
2008; Shibutani et al., 2008; Abbas et al., 2010; Centore et al. 2010; Jorgensen et al., 
2011; Oda et al., 2010; Terai et al., 2010).   Thus, it appears that as a whole, 
degradation of CRL4CDT2 substrates facilitates S-phase progression and DNA repair and 
that substrates may be targeted in a coordinated manner. In contrast, substrates of 
SCF TRCP1 and SCF TRCP2 (collectively referred to as SCF TRCP) appear to be much more 
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diverse with functions in distinct pathways resulting in, at times, contradictory effects on 
the cell cycle.  SCF TRCP substrates include I  (NF  signaling), WEE1 (CDK1 
inhibitor), CDC25 (CDK1 activator), -catenin (Wnt signaling), REST (neural 
transcription repressor), PDCD4 (translation inhibitor), claspin (DNA replication/repair) 
and Pro-casapase 3 (pro-apoptotic protein) (Busino et al., 2003; Dorrello et al., 2006; 
Peschiaroli et al., 2006; Tan et al., 2006; Tan et al., 1999; Watanabe et al., 2004; 
Westbrook et al., 2008).  While clusters of substrates which function in coordinately 
regulated pathways emerge (e.g. degradation of CDC25A and claspin at the end of G2), 
other substrates appear quite unrelated, and would require degradation at distinct time 
points.  The disparate nature of substrates suggests that the regulatory kinases, which 
function to phosphorylate substrates and thus control substrate binding to TRCP, play a 
dominant role in determining the timing of substrate degradation, rather than activation 
of ubiquitin ligase activity of SCF TRCP itself.  Thus SCF TRCP can regulate diverse 
substrates, as long as these substrates contain the required phospho-degron. 
 I suggest that CRL4VprBP function is likely more analogous to the SCF TRCP 
complex, rather than CRL4CDT2.  I base this on evidence from my own work, including the 
accumulation of VprBP in quiescent cells (Chapter 3) and a requirement for VprBP in cell 
proliferation (Chapters 3 and 4), indicating that VprBP may have functions at multiple 
phases of the cell cycle and may play apparently contradictory roles in promoting 
proliferation and maintaining quiescence.  Furthermore, VprBP is quite abundantly 
detected in virtually all adult mouse tissues, both in proliferative tissues such as intestine 
and bone marrow and in largely post-mitotic tissues including adult kidney, liver and 
brain.  While this is correlative evidence, expression patterns suggest multiple functions 
for VprBP in a wide variety of tissues.  Furthermore, VprBP has been identified in protein 
complexes with binding partners of diverse and seemingly unrelated function such as 
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Merlin, LGL1/2, and DYRK2 (Huang and Chen, 2008;Tamori et al., 2010; Maddika and 
Chen, 2009).  Because my model is that VprBP largely functions as part of a CRL4 
complex, I suggest that CRL4VprBP targets multiple proteins of diverse functions for 
degradation. 
 
Identification of bona fide CRL4VprBP substrates 
 Perhaps the greatest limitation for understanding the function of VprBP is the 
lack of validated CRL4VprBP substrates.  The Xiong lab has pursued several different 
avenues to identify substrate proteins including yeast two hybrid and mass spectrometry 
to identify co-immunoprecipitated proteins of the endogenous VprBP complex.  
Unfortunately, VprBP was auto-reactive in the yeast two hybrid assay.  Further, no novel 
VprBP-interacting proteins were identified in two separate mass spectrometry 
experiments examining the endogenous complex; only DDB1, CUL4A/B and CSN 
subunits were identified.  Because the sensitivity of mass spectrometry has increased 
significantly since the previous experiments in 2004 and 2007, we recently renewed 
efforts to identify VprBP substrates by TAP-purification of the VprBP complex.  This work 
is being directed by Dr. Tadashi Nakagawa, a post-doctoral researcher in the lab, who 
has purified the full-length VprBP construct, a mutant containing disrupted WDXR motifs, 
and a mutant lacking the C-terminal 598 amino acids (VprBPN909).  Preliminary results 
from these TAP experiment found a much larger number of proteins associated in these 
complexes than were uncovered in our previous mass spectrometry experiments.  
However, a number of published VprBP-binding proteins were not detected in the 
complex including Merlin, DYRK2, LGL1 and LGL2.  We have already validated Merlin 
and DYRK2 binding with VprBP by co-immunoprecipitation experiments, indicating that 
mass spectrometry of the TAP-VprBP complex is still missing known interactions.  
Furthermore, a survey of the literature finds relatively few examples where a substrate 
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has been identified by mass spectrometry of the E3 ubiquitin ligase complex 
(D'Angiolella et al., 2010); rather the vast majority of E3-substrate interactions are 
identified by mass spectrometry of the substrate complex.  I suspect this limitation has to 
do with the very transient nature of the interaction between E3 and substrate which 
greatly impairs attempts to co-purify substrate and ligase.  We hope that mutations 
which disrupt binding between DDB1 and VprBP (such as VprBPN909 and VprBPWDXA) will 
effectively trap VprBP-substrate interactions.  In addition to mass spectrometry-based 
approaches, future efforts could utilize an RNAi-based screen to search for proteins 
whose co-depletion rescues the cellular defects of loss of Vprbp (e.g. apoptosis and 
inhibition of cellular proliferation). 
An alternative hypothesis for VprBP function is that VprBP is not a substrate 
receptor for CRL4, but rather functions as an inhibitor of the complex, thus explaining 
why no substrates for VprBP have been discovered.  VprBP does appear to be unique 
among DWD proteins in that it is one of the largest DDB1-associated proteins and one of 
the most abundant, with stochiometric levels DDB1 in the VprBP immunocomplex.  
Could the function of VprBP be to regulate access of other DWD proteins to CUL4-
DDB1?  This model is indeed quite possible, though my prediction is that VprBP does 
function as a substrate receptor based on two lines of evidence: (1) The VprBP compex 
has been demonstrated by several groups to have ubiquitin ligase activity in vitro and in 
in vivo (Huang and Chen, 2008, Li et al., 2010), and (2) Viral proteins Vpr and Vpx have 
clearly been demonstrated to hijack the complex to polyubiquitylate UNG2 and 
SAMHD1, respectively (Ahn et al. 2010, Hrecka et al. 2011).  While several ubiquitin 
ligases have been reported to be hijacked by viral proteins (discussed in Chapter 1), to 
the best of my knowledge, no viral protein has been established to convert a ubiquitin 
ligase inhibitor into a substrate receptor.  I suggest that VprBP does indeed function as a 
substrate receptor and that current experimental approaches, including mass 
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spectrometric analysis of the VprBP complex, have simply not yet identified the targeted 
substrate(s). 
 Another approach that has effectively identified CRL substrates is through 
genetic analysis of phenotypes.  For example, depletion of CUL4 or DDB1 in C. Elegans 
resulted in a massive re-replication phenotype that led to the identification of CDT1 
targeting by CRL4 (Zhong et al., 2003).  For this approach to be effective, a phenotype 
needs to be associated with the accumulation of a dominant substrate in vivo.  We had 
hoped that the genetic studies I initiated would provide phenotypic clues to the identity of 
a CRL4VprBP substrate.  However, our observations in the developing immune system are 
largely consistent with cellular phenotypes observed following VprBP knockdown in 
cultured cells and did not provide a significant breakthrough in substrate identification.  
Clearly, a single genetic study is insufficient to fully investigate the diverse in vivo 
functions of a pleiotropic gene such a Vprbp.   Because VprBP likely targets multiple, 
varied substrates, we may find that loss of Vprbp in mice in a highly proliferative tissue 
such as the hematopoietic system yields a distinct phenotype from loss of Vprbp in 
brain, a largely post-mitotic tissue with high levels of Vprbp expression in adult animals.  
I would predict that loss of Vprbp in proliferative tissues results in defects in DNA 
replication/repair or mitogenic signaling, whereas in brain, katanin p60, which has 
microtubule-severing functions associated with axon formation, may be more significant.  
Thus, a thorough understanding of Vprbp in mice ultimately cannot be addressed by one 
genetic study, but will require examination of several different systems.  I suggest here 
two lines of research which could be conducted to address the function of murine Vprbp 
in vivo. 
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Future Genetic Studies 
Vprbp in hematopoiesis.  The data I presented in Chapter 4 provided solid 
evidence that Vprbp functions in the development of lymphocytes, and suggest perhaps 
a broader role in hematopoiesis.  Therefore, I suggest here experiments to examine the 
function of VprBP in hematopoiesis.  Ubc-CreERT2 is an appropriate driver for Cre 
expression because it is apparently quite well expressed in hematopoietic lineages 
(Ruzankina et al., 2007, Lum et al., 2007, Maillard et al., 2009, Thiel et al., 2010, 
Rahman, 2011 #2272) .   
To test for a role for VprBP in hematopoiesis, I would recommend modifying the 
genetic system I used by crossing conditional Vprbp mice with a reporter strain that 
express YFP following Cre-mediated excision, which are readily available from Jackson 
labs (Stock No. 006148).  This would significantly improve the existing system by 
allowing identification by flow cytometry or immunohistochemistry of individual cells 
which have been disrupted by Cre.  By specifically examining cells with active Cre (out 
of a mosaic population), this system would avoid diluting phenotypic effects that result 
from analyzing total tissue. Furthermore, once individual mutant cells could be identified, 
the dose of tamoxifen administered could be reduced thereby decreasing tam-
associated toxicity, as well as lessening the severity of phenotypes due to disruption of 
Vprbp in other tissues.   
Our current model posits that VprBP is generally required for cell proliferation.  If 
so, I would predict that disruption of Vprbp would prevent proliferation in myeloid lineage, 
in addition to lymphoid lineages.  To test this model, the proliferative capacity of myeloid 
cells, such as neutrophils should be examined.  Neutrophil granulocytes, which are an 
essential component of the innate immune systems, have a notably short half-life (2-5 
days or less) and undergo constant generation in the bone marrow (Barreda et al., 
2004).  To test if Vprbp is required for neutrophil proliferation in bone marrow, I would 
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identify Vprbp disrupted neutrophils (YFP+, Gr-1+, Mac1+ cells) following BrdU injection 
and determine if Vprbp disruption impairs neutrophil cell division by flow analysis.  I 
would predict that analyzing YFP+, Vprbp disrupted neutrophils after acute gene 
disruption (1-2 weeks following tam treatment) would demonstrate that these cells fail to 
incorporate BrdU and show increased apoptosis.  Further, I predict that mice analyzed at 
later timepoints (greater than one month following tam) would show a lack of Vprbp 
disrupted Gr-1+ Mac1+ cells due to selection pressure to retain an intact Vprbp locus.   
The predicted results for the neutrophil experiments would be consistent with my 
observations in B- and T-cell lineages.  It’s important to experimentally test this 
prediction, however, as results in Drosophila suggest that Vprbp is not required for 
proliferation, per se.   In addition, in my own experiments in 2-week-old mice, I did not 
see a change in BrdU incorporation in kidney, despite near complete absence of VprBP 
protein in the tissue (data not shown).  Thus, if neutrophil proliferation is not affected by 
Vprbp disruption, this finding would suggest that Vprbp is specifically required for 
proliferation of lymphoid lineages in adult mice and indicate that we should examine a 
role in lymphocyte-specific processes such as T-cell receptor and B-cell receptor 
signaling.  In contrast, a function for Vprbp in both myeloid and lymphoid lineages would 
suggest a broader function in hematopoesis.  In that case, I would recommend 
specifically examining upstream progenitor and stem cell populations. 
Hematopoietic stem cells (HSCs), which give rise to both myeloid and lymphoid 
lineages and have the capacity for self-renewal, primarily reside in bone marrow 
(Kawamoto and Katsura, 2009).  To test if disruption of Vprbp more broadly affects 
hematopoesis by preventing HSC proliferation, I would examine the HSC population in 
bone marrow by Lin- Kit+ Sca+ staining (negative for lineage specific markers, positive for 
c-kit and Sca-1).  I predict there would be increased apoptosis and lack of proliferation in  
YFP+, Vprbp disrupted HSCs.  To definitively prove a requirement for Vprbp in HSC 
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proliferation and differentiation, a reconstitution experiment, in which YFP+, Vprbp 
disrupted HSCs are transplanted into irradiated recipient mice, should be conducted.    
Further, a parallel analysis of VprbpF/F;VavCre+ mice should be conducted to rigorously 
show a role for Vprbp during hematopoeisis in embryonic mice. 
Once the cell populations which exhibit proliferation defects are identified, the 
molecular mechanisms which underlie the failure to proliferate could be addressed using 
the CreERT2+ system.  For example, we observe that loss of VprBP is associated with a 
complete loss RAC activity in cultured cells (Tadashi Nakagawa, personal 
communication).  In addition, previous genetic studies have established that loss of 
Rac1 and Rac2 causes a partial block of T-cell development at the CD4-CD8- stage 
(Dumont et al., 2009; Guo et al., 2008), largely consistent with the phenotypes I 
observed following disruption of Vprbp.  By sorting for YFP+ cells (e.g. thymocytes), it 
could be determined if acute Vprbp disruption causes loss of GTP bound RAC in vivo.  
Further, viral expression of a constitutively active form of RAC (L61RAC-1) in Vprbp 
disrupted mature T-cells could be tested for rescue of cell proliferation defects in vitro 
following T-cell activation.   
While it remains to be seen if RAC-dependent signaling accounts for the major 
proliferation defect in Vprbp disrupted mice, the ability to isolate Vprbp disrupted cell 
from a mosaic population would significantly improve our ability to determine the 
molecular mechanisms underling the phenotypes observed following Vprbp disruption.  
The hematopoietic system is an attractive system to functionally examine potential 
substrates or molecular pathways of VprBP because of the plethora of established cell 
markers to monitor each developmental stage, the relative ease of isolating 
hematopoietic cells, and the ability to conduct rescue experiments using in vitro culture 
systems.   
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Vprbp in the Hippo pathway.  The Hippo signal transduction pathway is an 
evolutionarily conserved pathway that constrains organ size during development and 
promotes cell contact inhibition (Saucedo and Edgar, 2007).  The Hippo pathway was 
first discovered in Drosophila; mutations in the key pathway kinases Hippo (homologous 
to mammalian MST1/2) and Warts (homologous to mammalian LATS1/2) were noted to 
cause significant overgrowth of epithelial tissue (Harvey et al., 2003; Wu et al., 2003) 
(Fig. 5.1).  The Hippo kinase cascade results in phosphorylation and nuclear exclusion 
of the transcription factor Yorkie (homologous to mammalian YAP) (Huang et al., 2005).  
A putative function for VprBP in the Hippo pathway is indicated by its binding with Merlin, 
which has been suggested to transmit signals from membrane receptors to Hippo in 
Drosophila (Hamaratoglu et al., 2006).  In addition, VprBP has been noted to bind with 
Drosophila Lgl (lethal giant larvae), which is also linked to the Hippo pathway and 
appears to genetically function as an inhibitor to Hippo activity (Parsons et al., 2010; 
Tamori et al., 2010).  In mammalian cells, all of the components of Hippo signaling are 
conserved, though the mammalian pathway appears more complicated and to vary 
depending on the context studied (Zhao et al., 2009).  Further, the role of Merlin in the 
mammalian Hippo pathway is less clearly defined and somewhat contentious 
(Benhamouche et al., 2010; Zhang et al., 2010).  In this section, I propose genetic 
experiments to determine if VprBP regulates the mammalian Hippo pathway.   
The best studied genetic system for examining the mammalian Hippo pathway is 
mouse liver.  Several groups have taken advantage of liver specific deletion of Hippo 
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Figure 5.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.  Model for the Hippo Pathway. 
(A) In Drosophila, genetic evidence indicates that the kinases Hippo and Warts regulate 
size control by inhibiting the transcription factor Yorkie, which is excluded from the 
nucleus when phosphorylated.  Merlin may function upstream of Hippo, potentially by 
mediating signals from membrane receptors.  Lgl, a known regulator of cell polarity, is 
proposed to inhibit the Hippo pathway.  VprBP has been found in separate studies to 
bind Merlin and to bind Lgl.  Overexpression of VprBP or constituatively active Yorkie 
can both rescue loss of Lgl in mosaic tissue analysis.   
 
(B)  In mouse liver, the homologs of Hippo, MST1 and MST2 function to promote YAP1 
phosphorylation in a LATS1/2-independent manner (LATS1/2 are homologous to Warts; 
YAP1 is homologous to Yorkie).  Based on cell fractionation experiments, a YAP1 kinase 
downstream of MST1/2 is proposed to exist.  LATS1/2 phosphorylates YAP1 in a parallel 
pathway which requires an activating phosphorylation on LATS1/2 by an unknown 
upstream kinase.  Loss of Merlin reduces LATS1/2 phosphorylation, and can be rescued 
by heterozygosity for Yap1 or by EGFR inhibitors.  I suggest experiments to test if VprBP 
inhibits Hippo signaling.
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components including Mst1/2 double knockout, Ww45 (homologous to Salvador) and 
Nf2 (which encodes Merlin) (Lee et al., 2010b; Zhang et al., 2010; Zhou et al., 2009).  In 
all three cases, gene deletion resulted in liver enlargement, oval cell expansion, and 
eventually led to hepatocellular carcinoma.  Further, transgenic expression of Yap1 in 
liver likewise increased liver size and eventually promoted hepatocellular carcinoma 
(Camargo et al., 2007; Dong et al., 2007). Despite several phenotypic similarities, there 
are some key differences in how gene deletion impacts the Hippo pathway: loss of 
Mst1/2 led to a complete loss of phosphorylated YAP1, whereas loss of Merlin only 
partially reduced the amount of phosphorylated YAP1 (Zhang et al., 2010; Zhou et al., 
2009).  Further, loss of Mst1/2 did not change the phosphorylation of LATS1/2, which 
suggests that LATS1/2 is not required for MST1/2 signaling in liver (Zhou et al., 2009).  
In contrast, loss of Merlin reduced LATS1/2 phosphorylation, but not MST1/2, indicating 
that Merlin possibly functions upstream of YAP1 via LATS rather than MST1/2.   
To examine a role for Vprbp in repressing Hippo signaling, I would generate 
VprbpF/F; Albumin-Cre+ mice to induce disruption of Vprbp in liver.  If Vprbp is indeed an 
inhibitor of the Hippo pathway, I would predict constitutive inhibition of YAP1 as well as 
reduced liver size and increased hepatocyte apoptosis.  Indeed, loss of Yap1 in liver was 
shown to cause increased apoptosis, increased proliferation (apparently to replace dying 
cells), and a failure to form functional bile ducts (Zhang et al., 2010).   
I would expect Vprbp disruption to result in similar phenotypes, if its major 
function is in regulating the mammalian Hippo pathway.  Liver to body weight ratio 
should be closely monitored and cytokeratin staining of liver tissue should be conducted 
to examine the formation of bile ducts.  Most importantly, YAP1 protein should be 
examined by both western blot and immunohistochemistry to determine if changes to 
YAP1 levels, phosphorylation or localization occur in Vprbp disrupted livers.  The levels 
of phosphorylated MST1/2 and LATS1/2 should likewise be examined to determine 
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through which signaling pathway Vprbp functions.  If indeed analysis of VprbpF/F; 
Albumin-Cre+ mice indicates that VprBP is a critical regulator of Hippo in mice, then 
overexpression of a S112A mutant of YAP1 (which cannot be phosphorylated and is 
therefore constitutively active) should rescue proliferation or cell death phenotypes in 
primary Vprbp disrupted hepatocytes.    
These experiments would definitively indicate if VprBP is a regulator of 
mammalian Hippo signaling, but would not reveal if this effect was due to its putative 
interaction with Merlin or LGL1/2.  To test this possibility, I would turn to primary 
hepatocyte cell culture to examine the role of Merlin in the Vprbp disrupted phenotype.  
The Merlin binding domain of VprBP has been mapped to residues 1311-1507 of VprBP.  
I would test if lentiviral expression of VprBP C can rescue disruption of Vprbp by 
examining apoptosis, proliferation and YAP1 localization in cultured hepatocytes.  
Rescue of Vprbp disruption by VprBP C expression would indicate that Merlin interaction 
does not mediate the effect of VprBP in the Hippo pathway.  In that case, I would instead 
focus on the role of VprBP-LGL interaction in controlling Hippo signaling.     
A possible caveat of these suggested experiments to genetically address Vprbp 
function in Hippo signaling is the possibility that pleiotropic phenotypes might mask the 
role of VprBP in this pathway.    If indeed Vprbp does have multiple, critical functions in 
most tissues, as is the case for Ddb1, pleiotrophic effects will be a complication in any 
genetic study.  Further genetic studies will still be invaluable for experimentally 
determining the in vivo function, but may not provide a crystal clear view of the 
underlying molecular mechanism.  In addition to thorough biochemical studies, the 
generation of knock-in mice with mutations that abrogate specific VprBP functions, but 
do not destroy the entire protein, may someday provide a more precise picture of the 
precise in vivo functions of Vprbp.  Ultimately, multi-pronged efforts combining 
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biochemical, molecular, and genetic approaches will be needed to fully uncover the 
function and mechanism of VprBP.   
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